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Red blood cells are transfused with the intent to improve the oxygen carrying capacity of 
blood during and after a clinical event which has led to severe bleeding, or in case of other 
types of anemia leading to cardiovascular symptoms. Over half a million red cell concentrates 
are transfused annually in the Netherlands (source: Sanquin Blood Supply Annual Report 
2011). With improvements in blood donation, storage and transfusion procedures, red cell 
transfusions have come a long way in terms of safety. Yet, donated transfused blood is a 
foreign, non-self tissue and therefore carries an intrinsic hazard for the recipient. One of 
these hazards is antibody formation. The aim of the studies described in this thesis was to 
examine the effect of transfusion related and patient specific risk factors on the occurrence 
red cell alloantibody formation (or alloimmunization). Because the design, analysis and 
interpretation of observational studies in clinical transfusion medicine present specific 
methodologic challenges, the methods of the studies are extensively discussed in several 
chapters of this thesis.
Red blood Cell AnTigenS And RiSk oF AlloimmunizATion
Red blood cells membranes have embedded carbohydrate, protein and lipid structures whose 
presence or absence is genetically determined. These so called blood group antigens, are 
mostly determined by single nucleotide differences in the encoding genes and, which as the 
name implies, define a person’s blood group type. Including the commonly known ABO and 
rhesus D blood group systems (or, major blood group antigens), there are 33 recognized 
blood groups systems (or, minor blood group antigens- for example other rhesus antigens 
like C, E, c, e; Kell; Duffy; Kidd groups) carrying around 600 antigens (Blood Transfusion in 
Clinical Medicine, 11th edition by P.L. Mollison). 
The distribution of minor blood group antigens (the focus of this thesis) varies in different 
populations: for example rhesus C- 68% of Caucasians, 27% blacks and 93% Asian are 
positive for this blood group. On the other hand, 29% of Caucasian, 22% of blacks and 39% 
of Asians are positive for rhesus E blood group type. Kell (K) is found in only 9% of Caucasians, 
2% in blacks and up to 25% in Arab population (Reid ME and Lomas-Francis C. The Blood 
Group Antigen Facts Book. Second ed. 2004, New York: Elsevier Academic Press). Thus, quite 
a few of these antigens are rare and or have a skewed presence in different ethnic groups. 
A non-self (or allogenic) blood group antigen comes in contact with the transfusion 
recipient’s immune system mostly via a blood transfusion and pregnancy; the recipient’s 
immune system may react leading to formation of antibodies against these foreign red cell 
antigens. These antibodies are called alloantibodies and the phenomenon- alloimmunization. 
Alloantibodies, which could cause such hemolytic reactions, are also called clinically relevant 
alloantibodies. Besides alloantibodies against incompatible transfusions and pregnancies, 
naturally occurring antibodies like IgM (immunoglobin M type) against the A and/ or 
B antigen occur in the absence of a previous red cell transfusion, previous pregnancy or an 
organ transplant (likely sources of red cell antigen exposure). Contact with such antigens in 
the environment that resemble non self red blood cell antigens (antigens located outside the 
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red cell membrane, or from other foreign substances such as bacteria) are held responsible 
for the formation of such naturally occurring antibodies. 
Alloimmunization has various clinical consequences. Alloimmunization may present itself 
as an acute (within 24 hours of transfusion) hemolytic reaction or a delayed (more than 
24  hours after transfusion) hemolytic transfusion reaction. Symptoms may include fever, 
rigors, nausea, hypotension, tachycardia, skin flushing, hemoglobinemia, hemoglobinuria 
and bleeding (Blood Transfusion in Clinical Medicine, 11th edition by P.L. Mollison). 
In the Netherlands, close to 800 cases of alloimmunization against red cell transfusions 
are reported yearly, according to the Transfusion Reactions in Patients (TRIP) national 
hemovigilance office. This reported number could well be an underestimation since the 
reporting from hospitals is voluntary.
Each antigen differs in its immunogenicity, with the ABO, D and Kell (K) highly immunogenic 
whereas the majority are not. The ability to detect transfusion related (or from previous 
pregnancy, previous organ transplant) as well as naturally occurring antibodies leads us to 
avoid subsequent hemolytic transfusion reactions by selecting donors with red cells lacking 
the antibody targeted antigen. Determining both the red blood cell type of patient and donor 
in principle also allows matching of transfused donor blood to patient’s blood type, and 
thus preventing alloimmunization in the first place. For example, the severely immunogenic 
antigen groups- ABO and rhesus D with significant percentages of the population that differ 
in their presence are as a standard tested for, both in patients that need blood and their 
donors. Transfusions are matched for these antigens; in other words patients thus receive red 
blood cell units that are compatible with their own ABO and D type. This is done not only to 
avoid a severe intravascular hemolysis mediated by the naturally occurring IgM antibodies, 
but also to avoid (further) (IgG) immunization against these antigens. 
Such preventive measures before an allogeneic red cell transfusion hence consist of 
routinely matching the recipient’s blood group type to the donor red cell unit. While ABO 
and D matching is practiced in all patients, additional matching is more sensible- a) for 
common, highly immunogenic antigens other than ABO and D like K and e antigens and 
b) in special patient populations with chronic requirement of blood transfusions (sickle cell 
anemia, thalassemia, auto-immune hemolytic anemia, myelodysplastic syndrome- CBO 
richtlijn- Bloedtransfusie 2011) as well as women in the reproductive age. The Danger Model 
theory of immune response1,2 suggests that the extent of the immune response depends 
not only on the exposure to a foreign antigen itself, but also on the immune modulating 
conditions surrounding that exposure- transfusion related and co-existing patient clinical 
profile. Identification of patients or clinical conditions that are associated with high risks for 
alloimmunization and subsequently transfusing these high risk patients with more extensive 
matched blood could be the third most likely and most cost-effective strategy to prevent 
alloimmunization. A first step for this strategy would be to define the transfusion and clinical 
risk factors and in this way identify the patients with the highest risk for alloimmunization. 
In this respect, female sex, diabetes, solid malignancies and progenitor cell transplants 
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were shown to be associated with a higher risk of clinical alloimmunization3; and lympho-
proliferative disorders and atherosclerosis with a lower risk of alloimmunization3. 
In studying clinical risk factors for an adverse event, (alloimmunization in this instance) 
case- control epidemiological study design (with its variants) and cohort design are logical 
and feasible study designs. A major pitfall of such case control study designs though is 
improper selection of a control patient population for comparisons with the case patients. 
It is essential that the control patients are a good representative sample of the population 
at risk for alloimmunization, or the source population. This less optimal sampling of control 
patients was a limitation of a study3 which examined clinical risk factors (or predictors) of 
alloimmunization.
ouTline oF THiS THeSiS 
The scope of the work described in this thesis is to examine whether potential transfusion 
related and clinical risk factors modulate the risk of alloimmunization in a general, previously 
not transfused, non alloimmunized population of transfusion recipients. In these studies 
we emphasize the methodological aspects of observational research in clinical transfusion 
medicine.
Briefly, in chapter 2, we presented the design of our case- referent study as a benchmark 
for the rest of the thesis. We then aimed to study the risk of alloimmunization and the 
number of transfusions, using a new user cohort study design in chapter 3. The aim of the 
case- referent study conducted in chapter 4 was to examine storage time of red cells as a risk 
factor of alloimmunization. In chapter 5, we examined the intensity (or the dose) of red cell 
transfusions and the risk of alloimmunization. The effect of concomitant immunosuppressive 
medications as a clinical risk factor for alloimmunization was studied in chapter 6. Finally, 
in chapter 7, we aimed to highlight the distinction between etiologic and prediction 
observational research in clinical transfusion medicine. 
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Individuals exposed to red blood cell (RBC) alloantigens through transfusion, pregnancy, 
or transplantation may produce antibodies against the alloantigens expressed by RBCs. 
Although the incidence of these events is debated and ranges between percentages of 
1-6% in single transfused patients and up to 30% in poly-transfused patients (e.g. sickle 
cell disease, thalassemia and myelodysplasia), they can pose serious clinical problems such as 
delayed haemolytic reactions as well as logistic problems e.g. to obtain timely and properly 
matched transfusion blood for patients in which new alloantibodies are detected. 
Rationale
It is known that the risk of a recipient to develop antibodies depends on dose and route of 
administration and the immunogenicity of the antigen, as well as on genetic or acquired 
patient-related factors. The latter factors however are ill defined and therefore we hypothesize 
that the particular clinical conditions (e.g. used medication, concomitant infection, and cellular 
immunity) during which transfusions are given may contribute to the risk of immunization. 
Research objective
Examine the association between clinical, environmental and genetic characteristics of the 
recipient of erythrocyte transfusions and the risk against immunization against erythrocyte 
alloantigens exposed to during that transfusion episode.
Study design
A nationwide multicenter case- cohort study.
Study population
Cases will be defined as first time alloantibody formers during the study period. Controls are 




Individuals exposed to red blood cell (RBC) alloantigens through transfusion, pregnancy, 
or transplantation may produce antibodies against the alloantigens expressed by RBCs. 
Although the incidence of these events is debated and ranges between percentages 
of 1-6% in single transfused and up to 30% in poly- transfused patients (e.g. sickle cell 
disease, thalassemia and myelodysplasia1), they can pose serious clinical problems such as 
delayed haemolytic reactions as well as logistic problems e.g. to obtain timely and properly 
matched transfusion blood for patients in which new alloantibodies are detected. Of course, 
prevention of alloimmunization by extended matching between donors and all transfused 
patients (i.e. on the basis of typing patients for the most relevant RBC antigens) would be an 
ultimate but complicated and costly solution. However, matching of donors only for patients 
who are defined to have a high alloimmunization risk would be a more feasible step forward. 
This strategy would be especially valuable because as soon as immunization for one antigen 
develops, additional immunizations tend to develop more frequently2,3. 
Characterization of patients and clinical conditions with high immunization risk can be 
derived from studying the possible correlations between the actual immunization and patient 
related factors (both genetic and acquired) and/ or transfusion associated situations. 
Such a study comparing immunized and non-immunized patients with a similar transfusion 
history will generate relative risk or relative protective factors. 
We expect a two-fold impact from our study: a) to identify a set of transfusion recipients 
who need to be extensively matched, and b) to help understand the mechanisms underlying 
the development of alloantibodies to erythrocyte transfusion.
2. RATionAle/ bACkgRound
Alloantibodies can lead to serious clinical consequences and logistic problems like obtaining 
properly and timely matched blood for the patients who do develop these antibodies. 
Prevention of such serious events is possible by extended matching and typing of donor’s 
blood against the patient’s for all the possible antigens, but this process is cumbersome and 
costly. Identifying a high risk group will be a feasible first target and advanced matching a big 
step forward, and the aim of our study. 
It is known that the recipient’s formation of antibodies depends on dose and route of 
administration and the immunogenicity of the antigen, but probably also on genetic or 
acquired patient-related factors. It has been shown that the number of transfusions also play 
an important role in alloimmunization against red blood cell, with the risk increasing with the 
increasing number of transfusions13. It is generally recognized that immuno- compromised 
patients have a lower risk to develop such antibodies.4 Relatively little is known, however, 
about other patient related risk factors.2,3,5-8 
A recent study examined such patient related risk factors in a case-control study among 
101 cases developing erythrocyte alloantibodies and 87 controls.9 In this two-centre study, 
patients with first time detected antibodies and at least one transfusion in the past were 
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compared with controls with a negative antibody screening in the same centre. After 
adjustment for a limited number of confounders, this study confirmed known risk factors 
for antibody formation such as female sex (increased risk, since women are more susceptible 
to exposure of alloantigens during pregnancy, miscarriages, abortions and child birth10); 
lympho- proliferative disease and leukemia (lower risk attributed to lymphocyte dysfunction 
by concomitant chemotherapy and suppression of the immune response11). Also new and 
partly unexpected risk factors were found, such as diabetes and solid tumors (both increased 
risk). Although the latter patients do undergo chemotherapy as well, in this group antibodies 
might develop more easily because of their chronic inflammatory state12. The limitations of this 
case-control study9, however, were i) the selection method for controls favored controls which 
had received more transfusions with also smaller transfusion time intervals as compared to 
the cases; ii) the relatively small number of patients reducing the detection of smaller relative 
risks; and iii) a relatively crude assessment of only a limited number of potential risk factors. 
Additionally the study design did not allow investigating the association with the actual 
factors at the time of the likely primary immunization / causal transfusion. We will not only 
try to confirm the observed potential risk factors in a larger cohort, but we aim to find other 
clinical, environmental factors as well as genetic factors. There is well documented evidence 
that certain HLA types are associated with enhanced response to red blood cell antigens 
like Kell, Duffy and Kidd14-16. HLA genes in this respect are particularly interesting because 
along with their polymorphisms, they have been shown to play an active role in autoimmune 
disorders and diseases which develop via T-cell mediated immunity.17 Moreover, several 
of these genes have been identified in human studies to be associated with susceptibility 
and resistance to mycobacterial infection. Another strong correlation was shown between 
immunodeficient genotype (interferon gamma receptor 1 deficiency) and responsiveness to 
mycobacterium antigen.18 Finally, specific SNP associations have been identified to play a role 
in viral immunity and variations in both humeral and cellular immunity following measles 
vaccination.19,20 Although many genes are involved in the immune system, SNP’s in genes 
(e.g. coding for HLA types) that modulate specific and innate immune responses will be of 
the first targets in our analyses. We hypothesize that this will yield genetic modulators on 
the patients’ humoral response to particular erythrocyte expressed antigens but maybe even 
more broadly to other antigens as well.
By our questionnaire we will query environmental, life style factors and socio- economic 
status (SES) as those have been suggested to modulate the immune response. Environmental 
factors such as exposure to helminthic, fungal and parasitic infections do play a role 
in modulating the general set point of the immune response at young age21. The same 
is true for living in unsanitary conditions and for unhygienic occupations throughout life22 
Additional information on “immune modulating” conditions during childhood and youth 
will be collected from the vaccination status, completion of the vaccination programme, 
presence of pet animals, place of residence (urban/ rural) and visits to day care centers during 
childhood. The questionnaire will add to the knowledge to these possible confounders in 




The aim of the project is to examine the association between clinical, environmental and 
genetic characteristics of the recipient of erythrocyte transfusions and the risk of immunization 
against erythrocyte alloantigens that he/she was exposed to during that transfusion episode.
4. meTHodology
4.1 Study design and study population
We will perform a retrospective matched case- cohort study at hospitals nationwide from a 
period January 2005 to December 2011. Large red blood cell using hospitals will be selected 
as study bases. The study cohort will comprise of consecutive red blood cell transfused 
patients at the study center. 
Cases are defined as first time ever irregular red blood cell antibody formers, with no 
prior history of red blood cell transfusions and alloimmunization before the study period.
Controls will be all consecutive transfused patients who had received their first and 
subsequent red blood transfusions at the study center with no prior history of red blood cell 
transfusions and alloimmunization. 
Observational studies, if well conducted, are equipped to examine interesting transfusion 
research questions. With that in mind, we chose a case- cohort study design for our study. 
With the help of such a design, we can compare the cases occurring in a red blood cell 
transfused cohort with a randomly selected sample of the cohort. Using such an approach, 
for any one given case, we will select 2 controls that have had at least the same number or 
more transfusions than the case itself. This approach has following advantages:
This ensures that all the patients in the transfusion cohort with same or higher number 
of transfusions have an equal chance of being picked as controls. In essence, any member of 
the cohort who has been at a similar transfusion risk (of alloimmunization) at some point in 
their transfusion history can be selected as a control.
Cases also have an equal chance of getting selected as controls for other cases.
This study design minimizes the selection bias, if any. Such a study design allows us to 
include a number of patients which is sufficient to detect smaller effects and to adjust for 
other risk factors, as well as document potential risk factors extensively. 
4.2 matching
We will take in to account the number of transfusions a particular case received until the 
antibody forming episode, and match the 2 cases (selected per control) on the same number 
of transfusions. 
To account for inter- hospital differences nationwide, we will also match the cases 
and controls on the site/ study center. (Figure 1)
4.3 implicated Period
To examine the immune-modulating clinical risk factors surrounding the transfusions 
preceding the date of alloantibody formation, we will define a clinical risk period or an 
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Figure 1.Flowchart of Study Design for the matched control group
Transfusion
Type and screen negative
First time Alloantibody found No alloantibody found
Received previous transfusion (N)
Enroll CASE
Received previous transfusion (N)
Enroll CONTROL
Figure 1. Flowchart of Study Design for the matched control group
implicated period of alloimmunization during which the case would have formed an irregular 
red blood cell antibody. This period would be the time (in days) between the date of a first 
ever positive screen for alloantibody to a calendar date 30 days before that positive screen. 
We will also introduce a lag period of minimum 7 days between that first ever positive 
screen and the last ever transfusion (implicating transfusion) before that positive screen. 
(Figure 2) This is to ensure that a patient’s immune system has adequate time to respond to 
the transfusion exposure. 
We will define a similar implicated period in the matched controls as well, retrospectively 
from the “implicating transfusion” to 30 calendar days back. (Figure 2)
4.4 First time formed alloantibody
Our endpoint for cases, or first time formed irregular red blood cell antibodies is defined as 
clinically significant antibodies as screened by a three cell serology panel at 37 degree Celsius. 
All patients were routinely screened for alloantibodies, which is repeated at least every 72 
hours, if further transfusions as required. The antibodies are screened for by a three cell panel 
21
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4.3 Implicated Period
To examine the immune-modulating clinical risk factors surrounding the transfusions 
preceding the date of alloantibody formation, we will define a clinical risk period or an 
implicated period of alloimmunization during which the case would have formed an 
irregular red blood cell antibody. This period would be the time (in days) between the 
date of a first ever positive screen for alloantibody to a calendar date 30 days before that 
positive screen. We will also introduce a lag period of minimum 7 days between that first 
ever positive screen and the last ever transfusion (implicating transfusion) before that 
positive screen. (Figure 2) This is to ensure that a patient’s immune system has 
adequate time to respond to the transfusion exposure. 
We will define a similar implicated period in the matched controls as well, retrospectively 
from the “implicating transfusion” to 30 calendar days back. (Figure 2)
Figure 2: Implicating period of clinical data collection
Figure 2. Implicating period of clinical data collection
including an indirect antiglobulin test (LISS Diamed ID gel system) and subsequently identifies 
by a standard 11 cell panels in the same gel system.
4.5 data acquirement, measurements and handling
Transfusion cohort data will be acquired from the hospital blood transfusion services and on 
site patient records. Second we will use data from a patient questionnaire. Thirdly, we will 
determine the patients’ racial background from blood of the included and consenting patients. 
4.3.1 Patient medical history and records
Potential clinical risk factors include hematological, oncological, surgical and medicinal 
data as well as auto- immune diseases and related conditions at the time of the implicated 
(likely causal) transfusion. Factors and conditions that will be actively scored are, infections 
(including the causal microorganisms) and active / chronic allergies (including the if known 
antigens), fever, cytopenia(s), systemic inflammatory response (a clinical response to a (non)-
specific insult of either infectious or noninfectious origin), peripheral blood progenitor cells 
transplantation (autologous or allogenous), multi trauma, splenectomy, solid malignancies, 
autoimmune disorders (rheumatoid arthritis, diabetes mellitus type 1 etc.), chemotherapy, 
immunosuppressive drugs, cytostatics and antibiotics will be studied.
4.3.2 Questionnaire
Participants will be asked to fill out a printed questionnaire. The participants have also the 
option to fill in a web-based questionnaire, which will be accessible via a link provided in 
the information letter. After identification of control patients a similar mailing will be sent to 
these controls 
Environmental and life style factors like vaccination status, previous pregnancies in case 
of females, level of education and current professions (as a proxy for socio- economic status) 
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will be obtained via the patient information questionnaire. The questionnaire will add to the 
knowledge to these possible confounders in cases and controls. 
In general, many questions will involve “life-time” risk factors and information 
and are not particularly targeted at the time of implicated episode. 
racial confounder
Based on the knowledge that different ethnicities have varying frequencies of erythrocyte 
antigens, a so- called mismatch between a donor from one particular ethnicity and the 
recipient of another ethnicity does play a role in developing immune response to donor 
erythrocytes. Therefore, we will also attempt to document racial mismatch leading to red 
blood cell alloimmunization. This is attempted by one question in the questionnaire but will 
foremost rely on the blood group typing which usually determines the ethnicity.
blood research and sampling
To investigate the effect of genetic factors on the risk of the development of alloantibodies, 
we will collect blood samples from all participants for extensively typing the blood to get 
an antigen profile and to look at genetic markers which influence immune system and 
vaccination efficiency. SNP’s in candidate genes (e.g. coding for HLA types) modulating 
specific and innate immune responses will be assessed. Biomarkers typical for the activity 
of the immune response: cytokines and titers of antibodies against common (vaccinated) 
antigens can later be determined in the plasma and serum that are stored as well. 
4.6 Statistical analysis
We expect to include a total of 500 case patients and 1000 controls. 
Logistic regression models will be used to assess the association between the risk to 
develop antibodies and potential risk factors, adjusted for other risk factors and for the 
number of exposures to the antigen.
We will examine the association between the risk factor and alloimmunization using 
logistic regression.
We will also make a selection of all cases and controls on the most frequently found 
antibodies and if the relative impact of risk factors and immune modulators on the risk of all 
the antibody types( in separate analysis) is in the same direction, we will make a generalized 
observation. 
With 1500 patients, and the conventional 80% power and a p-value of 0.05, we will be 
able to detect effects (odds ratio) of dichotomized risk factors of 1.35 or higher. 
An additional analysis will be performed along the lines of a “case-crossover” design 
within the case patients. The “Hazard Period” (time period right before the detection of 
a positive antibody) will be compared to a “Control Component” (a specified time period 
other than the Hazard Period) in the case patient’s medical history and the risk ratio for the 





The study will have a multicenter design subjecting patients to a questionnaire and additional 
blood sampling. After approval by the central MEC of the LUMC, the study clearly requires a 
local Medical Ethical Committee approval for each site that detects an probable transfusion 
mediated alloimmunization. Help of local investigators, usually the local hematologist or 
clinical chemist in charge of the transfusion laboratory will be recruited to substantiate 
implementation of the study at the various sites. Each local investigator will in fact be 
responsible for ensuring that the study will be conducted in his centre in accordance with the 
protocol, the ethical principal of the Declaration of Helsinki, current ICH guidelines on Good 
Clinical Practice and applicable regulatory requirements. 
5.2 Recruitment and Consent
Data will be collected at each hospital site, Sanquin and from medical records and files. All 
data will be coded for privacy reasons. As said, after identification of cases and controls, 
patients will be sent a short and concise letter and an information brochure explaining the 
purpose of the study. This letter will be combined with the questionnaire and foremost – an 
answer card expressing willingness or refusal to participate in the study to fill in and return 
to the study’s contact address. Participants, moreover, will have an option of filling in the 
questionnaire via the study’s website. The web link access will be explained in the patient 
information. After receiving a patient’s positive response to our request to participate, a 
follow- up call will be made by the investigator to answer any additional queries and if 
applicable to make an appointment for the blood taking. The patients would be invited 
to LUMC or the participating centers for blood taking. Additionally to the signed answer 
card for blood taking, patients would be informed about the study once again at the blood 
taking appointment, and a final consent form in presence of the study coordinator and data 
manager will me signed before the blood taking commences. Proper tubing and transfer 
material will be provided to the non- LUMC sites. 
5.3 The patient burden
The reading of the information and completing the questionnaire (estimated to take about 
10 minutes) will be of minimal patient burden or stress and is absolutely voluntary. Apart 
from the questionnaire, the protocol involves a single blood sampling of 25 ml as main 
discomfort for cases and controls. However, the blood taking will preferably be combined 
with a regular control and if possible a blood sampling. 
The blood taking will be organized centrally at the LUMC upon invitations. There are no 
further interventions within the study protocol. The study has absolute minimum invasive risk 
for the patients.
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5.4 medical information, data and sample handling and Reports
1. Per patient an electronic Case Record Form (CRF) with a unique study number (identifier) 
will be made. The CRFs will be subjected to independent data management. The principal 
investigators Anske van der Bom en J.J. Zwaginga, will be responsible for the CRF and 
data management. 
2. Patient-identifying parameters such as name, the hospital patient number and the 
full birth date will not be entered and found in the electronic CRF. The key between 
these identifying data and the unique study number will be only available to the data 
management at the department of Epidemiology. These patient identifying parameters 
are only needed for sending the questionnaire and making an appointment for blood 
taking which will be done by the data management. The blood taking and further 
sampling will involve relabeling of the tubes to the specific study number. 
There will be a provision to keep the patient personal details for the entire duration of 
storage of blood samples, with a possibility to track back and indentify the patients with 
their blood samples. Coding measure will ensure that this information is not available to a 
third party and is only accessible via an encoding key to the principal investigators of the 
R- FACT study. Individual medical and investigational information obtained during the study 
is considered confidential and disclosure to third parties is prohibited. The described strategy 
will guarantee effective study of data together with maintaining optimal patient privacy.
The blood samples will be stored in state-of-the-art storage facilities at the LUMC, with 
storage management software for 20 years.
The research, patient information, blood sampling and storage will be conducted in 
accordance with LUMC’s Good Research Practice guidelines.
5.5 Withdrawal of individuals
Subjects can decide to have their samples removed from the serum, plasma, DNA and RNA 
bank and thus from further research in the future at any time and for any reason, i.e. meaning 
without consequences for their further clinical treatment. 
5.6 independent physician 
Before consenting, patients can gather information or advice from the investigator but also 
from an independent physician: Tanja Netelenbos, MD. This name will be provided in the 
patient information.
5.7 objection by minors or incapacitated subjects
Not applicable






6. AdminiSTRATiVe ASPeCTS And PubliCATion
6.1 Handling and storage of data and documents
Data handling will comply with the Dutch Personal Data Protection Act.
A data-manager (employed on the project) and the PhD fellow will extract data from 
the study sites, and recode patients and locations to unique study codes under which non- 
patient identifying data are filed in a CRF per patient. 
There will be no specific physical CRFs because of the massive patient / control numbers 
and electronic data sets can be often automatically extracted from the patient information 
systems present in most hospitals. 
6.2 Amendments
All amendments will be notified to the MEC that gave a favorable opinion. 
6.3 Annual Progress Report
The investigators will submit a progress summary of the study to Sanquin as sponsor of 
the study regularly. Information on inclusion of cases and controls, other problems and 
amendments will be provided as required by the regional and local MEC’s.
6.4 end of the study report
The investigator will notify the accredited MECs of the end of the study within a period of 8 
weeks. The end of the study is defined as the last data collected from medical records and 
case- control questionnaires.
6.5 Public disclosure and publication policy
The final publication of the study results will be written by the study coordinator(s) on the 
basis of the statistical analysis performed. A draft manuscript will be submitted to all co-
authors for review. After revision the manuscript will be sent to a peer reviewed scientific 
journal.
Any publication, abstract or presentation based on patients included in the study must be 
approved by the study investigators and collaborators. 
7. eXPeCTed ReSulTS
Our case-cohort study will quantify and characterize risks of patients and conditions for 
transfusion associated alloimmunization. Although a prospective serology study involving a 
first transfused cohort, would be most preferable to add to the insight in primary immunization 
(risk). However, 50% of first transfused patients never need new blood again, and escape 
follow up if not recalled. Moreover, the occurrence for the other 50% of the following 
26
transfusion period is quite variable. Therefore, a prospective study is viewed as cumbersome. 
On the more practical side for a case control study, 50% of the transfused patients have 
been transfused before and these in principle are eligible as case or control patients. Indeed 
in accordance by the rules for inclusion these patients are already transfused at two different 
periods at least. Therefore, if we can define risk factors for alloimmunization then advanced 
matching of blood donors for this group should be regarded as valuable. Finally, strong 
synergy will be obtained between our study and the MATCH study by Schonewille et al. In 
the latter study, logistical / cost/ and benefit aspects of advanced matching after formation 
of a first antibody will be determined 
Our study will contribute to classifying patients who could benefit from additional or 
extended typing and donor matching to prevent alloimmunization. We envision to contribute 
to a matching policy based on a prognostic risk score for immunization in general transfused 
patients. 
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Patients receiving red blood cells may form antibodies against the alloantigens expressed 
by red blood cells, with the risk of serious morbidity and the need for extensive phenotype-
matching in subsequent transfusions. The incidence of alloimmunization is considered 
variable for specific patient groups and for first time antibody formation. We therefore 
studied the cumulative incidence of the first formed alloantibody as a function of red blood 
cells exposure.
methods
We performed a new user cohort among all previously non-transfused non-alloimmunized 
patients that received non-extended matched (ABO and RhD) red blood cells transfusions 
from January 2005 to December 2009 in our university medical centre. Alloimmunization 
incidences were estimated by Kaplan-Meier survival-analysis. 
Results
A total of 3002 previously non- transfused patients received 31,103 red blood cell units. A 
first time alloantibody forming event was experienced by 54 (1.8%) patients. The cumulative 
incidence of alloimmunization was 1.0% at 5 units, 2.4% at 10 units, 3.4% at 20 units, and 
6.5% at 40 units of red blood cells transfused.
Conclusion
The risk to develop a first red blood cells alloantibody increases up to the 40th transfusion and 




Patients exposed to red blood cell alloantigens by transfusion, pregnancy, or transplantation 
may produce antibodies against alloantigens expressed by red blood cells. These can cause 
acute and delayed hemolytic transfusion reactions and potentially serious morbidity and even 
mortality. Additionally, alloimmunization makes more extensive matching of subsequent 
transfusions necessary. 
Transfusion mediated alloimmunization could in theory be prevented by exact matching 
of all donor blood to the recipient’s phenotype. Implementation of such a strategy, however, 
will be laborious and cost- consuming and its logistical burden may hamper the timely 
availability of matched blood for patients. 
For some transfusion populations for e.g. sickle cell anemia and thalassemia, matching 
for Rh and K antigens to reduce the high immunization incidence associated with these 
diseases is often performed in most high income countries. We could maximally prevent 
alloimmunization by administrating matched blood to patients that are particularly at risk 
for alloimmunization, based on their clinical and transfusion risk factors. To estimate the 
feasibility of such an approach, an accurate antibody incidence measurement is an essential 
starting point. The reported frequency of red blood cell alloimmunization, however, varies 
considerably from 2 to 21%.[1-6] Besides, differences in study design and populations studied, 
the exact number of received transfusions before antibody formation is often unknown or 
poorly documented in many studies. Increased exposure to red blood cell antigens i.e. more 
red blood cell transfusions are likely to cause a higher risk for alloimmunization. Also, other 
studies included patients with already formed antibodies [7], or patients receiving large 
amounts of transfusions due to their predisposing indications [6, 8, 9]. 
Considering that red blood cell transfusions likely determine exposure to alloantigens 
and the risk for subsequent antibody formation and that preventative matching will alter 
the observed alloimmunization risk, we aimed to study the incidence of first alloantibody 
formation due to only ABO and D matched red blood transfusions in a general patient 
population from their first transfusion onwards. We also studied the incidence among females 
in the reproductive age for whom red blood cell transfusions are additionally matched for 
K antigen. 
meTHodS
Study design and study population
We performed a retrospective incident new user cohort study among consecutive transfused 
patients at the Leiden University Medical Center (LUMC), the Netherlands from January 2005 
to December 2009, to study adverse events (alloimmunization to red blood cell transfusions) 
among first time red blood cell transfused patients in an electronic patient follow up database.
[10, 11] Eligible were all patients who received their first ever red blood cell transfusion 
within the study period in our centre. Transfusions were included only if they were preceded 
by a negative antibody screen and followed by a post transfusion antibody screen. 
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Patients who routinely received Rh phenotype (C, c, E and e) and K red blood cell 
transfusion, e.g. haemoglobinopathies and women who received intra uterine transfusions 
(IUT) were excluded. We also excluded infants under 6 months of age because they are 
presumed to have a reduced capacity to form red blood cell antibodies as their immune 
system is not fully developed [12-14]. According to Dutch transfusion guidelines (24), apart 
from ABO and RhD, K antigen blood group matching is mandatory since 2004 for female 
patients in the reproductive age (≤45 years). We did not exclude women who received ABO, 
RhD and K matched blood but analyzed them separately from the main cohort. 
First time alloantibody
The endpoint of our study was the first time post-transfusion formation of clinically 
significant red blood cell alloantibodies as screened by a 3 cell serology panel at 37 degree 
Celsius, in patients with prior negative red blood cell antibody screens. All patients were 
routinely screened for alloantibodies before transfusion which is repeated at least every 72 
hours, if further transfusions are required. The antibodies are screened for by a 3 cell panel 
including an indirect antiglobulin test (LISS Diamed ID gel system, Murten, Switzerland) and 
subsequently identified by standard 11 cell panels in the same gel test system. Additional 
techniques such as Poly-ethylene glycol, Bovine serum albumin and enzyme method were 
used when required. Non-red blood cell transfusion induced antibodies (5 cases of anti-D by 
passive acquisition), antibodies against low-frequency antigens that are not routinely present 
on antibody screenings panels (12 cases of anti Wra) and cold-reacting (12 cases) antibodies 
were not classified as endpoints.
data acquisition
All data on antibody screening, antibody identification and transfusions were routinely 
recorded in the laboratory electronic data system General Laboratory Information 
Management System (GLIMS). We gathered transfusion dates for every transfused red blood 
cell unit, dates and results of antibody screens, antibody specificity, dates of birth and gender 
of all transfused patients. 
Statistical analyses
The incidence of alloimmunization was estimated using Kaplan-Meier survival tables.
The cumulative transfusion exposure expressed as cumulative units of red blood cells 
transfused was used as the time axis.
We calculated incidences of new antibody development among all males and females 
older than 45 years. In addition, women under 45 years of age who had received K-matched 
red blood cells were analyzed separately. The association between sex and age of the patients 





After careful exclusion of patients that had received transfusions that had extended antigen 
matching, infants and patients without post-transfusion antibody follow-up (Table 1), the 
study cohort comprised of 3002 patients who had received a total of 31,103 red blood cell 
transfusions in the 5 year study period with a median of 6 units per patient (range 1-133). 
The main cohort comprised of almost twice more men than women, since the women with 
child bearing potential (under 45 years) were analyzed as a separate cohort on account 
of receiving transfusions that had limited antigen matching. After the first transfusion the 
median antibody follow-up period was 60 days and comparable for men (55 days) and 
women (69 days); (log rank p=0.12) (Table 2).






Number of patients (%) 1929 (64) 1073 (36) 3002 510
Age in years (median, IQR) 60 (44, 70) 65 (56, 74) 62 (51, 71) 30 (15, 37)
Cumulative units 20,960 10,143 31,103 5093 
Units per patient (median, IQR) 7 (4, 13) 6 (4, 11) 6 (4, 12) 6 (3, 12)
Follow-up period (median, IQR)1 55 (13, 256) 69 (14, 287) 60 (13, 266) 147 (22, 527)
Patients forming first antibodies (% ) 36 (65) 18 (35) 54 7
Sensitization frequency (%) 1.9 1.7 1.8 1.4
1 Follow-up period in days from first transfusion to last antibody screen in non-immunized patients 
and to first positive antibody screen in immunized patients.
IQR – Inter quartile range







Intrauterine transfusions 49 8480
Infants <6 months of age 1089 7391
Patients with pre-transfusion positive screens 127 7264
Patients without antibody follow-up after a single transfusion event 3752 3512
Women ≤45 years of age (analyzed separately) 510 3002
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In 54 patients (1.8%) 69 clinically significant antibodies were detected (Table 3). Single 
antibody specificities were found in 40 patients and multiple specificities in 14 patients. 
Multiple antibody combinations occurred with Anti E in 13 of 14 cases. Patients who 
developed antibodies had received a median of 6 red blood cell units (IQR 4, 10) and non-
antibody formers had had a median of 6 red blood cell units (IQR 3, 11) units. Among women 
aged less than 45 years 7 women (1.4%) formed 9 alloantibodies (Table 3). We recorded 
6 men and 2 women with a first time alloantibody formed in less than 2 weeks of their first 
transfusion at our center.(3x anti-Jka, 2x anti- E, 2x anti- Lea and 1x anti-M). one male patient 
formed an anti-Cw after receiving 66 red blood cell units in 8 transfusion episodes.
The eventual cumulative incidence of alloimmunization as a function of exposure to the 
number of units, amongst 3002 red blood cell recipients was 1.0% at 5 units, 2.4% at 
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Figure 1: Red blood cell alloimmunization incidence in general red blood cell 
transfused population according to transfused units 
 
 
Addendum to figure 1 
Number of patients at risk at various cumulative transfusion units: 





Figure 1. Red blood cell alloimmunization incidence in general red blood cell transfused population 
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Incidence of alloimmunization (95% CI)
Men 
(n=1929)




Women ≤45 years 
(n=510)
5 1.0 (0.9-5.6) 1.2 (1.1-8.4) 1.0 (0.9-3.8) 0.8 (0.7-20)
10 2.4 (2.1-5.7) 2.4 (2.3-9.7) 2.4 (1.8-4.2) 2.5 (2.4-16)
20 3.4 (3.1-8.0) 3.5 (3.3-15) 3.4 (2.6-5.9) 2.5 (2.4-16)
30 6.5 (4.9-11) 5.0 (4.9-21) 5.8 (4.4-9.1) -
40 6.5 (4.9-11) 7.4 (7.1-24) 6.5 (4.9-9.9) -
10 units, 3.4% at 20 units and 6.5% at 40 units of red blood cells transfused and was 
comparable for men and women (Fig. 2 and Table 4). In women aged less than 45 years 
(n=510), who had received K-matched transfusions, the incidence was 0.8% at 5 units 
and 2.5% after 10 units of red blood cells transfused (Fig. 2, Table 4). No association of 
age, categorized as young (<= 30 years), middle (> 31-60 years) and old (> 61 years) was 
found in the total study population with incidence of alloimmunization (log rank p= 0.18). 
Comparing men under 45 and over 45 years of age, again no association between age and 
alloimmunization was noticed. (Log rank p= 0.5)
Table 3. Specificity and frequencies of antibodies among routine (ABO-D) and extended (ABO-D, K) 
matched patients between 2005-2009 at LUMC, Leiden
Alloantibody 
specificity
ABO, D matched ABO, D, K-matched
Men Women Total Women ≤45
E 17 10 27 4
K 10 5 15 0
Jka 4 2 6 1
Cw 4 1 5 0
M 3 1 4 0
C 1 1 2 0
c 1 1 2 3
S 0 1 1 1
Fya 1 0 1 0
Lea 2 0 2 0
e 2 0 2 0
Lua 1 0 1 0
Kpa 1 0 1 0
Total 47 22 69 9
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diSCuSSion
Our study, in general non-transfused and non-immunized transfusion recipients, demonstrated 
that the risk of first time alloimmunization to red blood cell antigens increases to 6.5 percent 
with the number of red blood cell transfusions up until 40th unit. This immunization rate 
was comparable for men and women over the age of 45 years as well as among different 
age groups. Young women who additionally received K- matched transfusions showed an 
immunization risk of 2.5% at the 10th transfusion, which was comparable to men and older 
women who received equal amounts of only ABO-D matched transfusions.
The alloimmunization risk to red blood cell antigens is debated and is suggested to be 
dependent on other factors such as the population studied, gender and genetic background. 
The number of transfusions however, seems most likely to have a major influence [7, 9, 15, 
16]. Indeed, the incidences reported in several studies on transfused patients seem to indicate 
that the risk of alloantibody formation rises with an increasing number of transfusions. 
In sickle cell disease patients, Sarnaik et al. reported alloimmunization frequencies up 
to 11.5  percent, with increasing number of red blood cell transfusions [15], Reisner et 
al reported a 10 percent immunization rate in less than 50 units transfused [17] and in 
another study the rate of alloimmunization increased exponentially with higher numbers of 
transfused units [9]. In addition, Hoeltge et al showed, in a general transfused population, 
that the number of antibodies in a patient was positively correlated with the mean number 
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Figure 2: Red blood cell alloimmunization incidence in men, women >45 years (ABO, D 
matched) and women ≤45 years (ABO, D and K matched) according to transfused units 
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and women ≤45 years (ABO, D and K matched) according to transfused units
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of red blood cell transfusions [16]. In these studies either the antibody specificities were not 
reported or clinically not- significant antibodies were included. Fluit et al, studying antibody 
specificities comparable to our study, reported an increase in first immunization frequencies 
from 4 percent before the 10th unit to 14 percent before the 40th unit.[7]. In lesser transfused 
populations (medical, obstetrics, trauma, elective surgery patients), as compared to the heavily 
transfused groups mentioned above, prospectively studied alloimmunization was described 
between 3 percent after a maximum of 24 units [18] and 8 percent after a maximum of 
10 units [19]. In these two studies, however, more than 30 percent of patients had a pre-study 
transfusion history. The fact that our study comprised of a non-transfused population, likely 
explains our overall lower immunization rate. Seemingly in contrast with our findings, a 
recent study addressing this issue proposed that the number of transfusions was only a weak 
determinant of alloantibody formation [5]. In the latter study however, it is unclear how the 
patients with hemoglobinopathies and infants were dealt with. Such patients, along with 
patients that have previously formed antibodies – who were documented in the study- are 
likely to be receiving broader matched blood. Matching on more blood groups will decrease 
alloimmunization risk. Compared to other studies, we specifically excluded patients who 
had received extended matched blood for various chronic conditions. In addition, patients 
with previous alloimmunization were excluded, because of their enhanced immune response 
against donor red blood cell alloantigens compared to first antibody responders [20, 21]. 
In our data, we show that the association of the immunization rate and the number of 
transfusions is not weak, and increases up to 40th transfusion. 
Finally, our study also showed a lower alloimmunization frequency among women aged less 
than 45 years of age, compared to the general female population (1.4 percent vs.1.7 percent), 
and an immunization rate of 2.5 percent after 10 units. The effectiveness of the current 
matching policies can be seen in these women where no K antibodies were observed. 
A strength of our study was using the incident new user cohort study design, that reduces 
the investigator error as well as avoids selection bias, without compromising on study validity.
[10, 11] Our data collection approach allowed a prospective follow up of previously non-
transfused and non-immunized patients during subsequent transfusions up to the appearance 
of a first alloantibody. We thus feel that this cohort represents the general transfused 
population and is appropriate to study the incidence of first time alloimmunization. Another 
strength of the study is that the incidence of alloimmunization increased with the increased 
number of units despite the median and range of red blood cell units being relatively similar 
among men, women > 45 years and women < 45 years of age. 
Although we did exclude all patients who had received transfusions before 2005, there 
could be a possibility that the patients entering the cohort have had transfusions prior to the 
start of study period in other hospitals. 
In addition, the incidence of alloimmunization, in the antibody forming patients as well 
as in the patients without observed alloimmunization in our study, may be under-estimated, 
because antibodies can stay undetected due to variable follow up intervals after transfusion, 
e.g. between 1 and 1825 days in our study. Moreover, the time that is needed before 
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antibodies can be detected differs and once formed they can disappear again, depending on 
antigen types [22]. This inherently will lead to a number of undetected alloimmunizations and 
thus, our presented results could be an underestimate of actual incidence. 
Our data being retrospectively acquired unfortunately did not allow for a comprehensive 
check on previous pregnancies. But we did exclude women receiving Intra Uterine transfusions 
and pre-transfusion antibodies. Additionally, we also analyzed women under 45 cohort 
separately and it did not show different results. Pregnancy induced antibodies can lead to an 
overestimation of transfusion induced first time alloantibody respondents. We, however, feel 
that this potential problem plays a minor part in our study. 
Alloimmunization to red blood cell transfusions is the single largest transfusion adverse 
reaction category reported in the Netherlands every year, since 2002 (23). Accurate incidence 
figures of alloimmunization provide a good platform to further study clinical implications and 
environmental risk factors of all immunization. 
We conclude that the risk to develop alloantibodies increases with the cumulative number 
of red blood cell transfused units. This risk increases at least up to 6.5% at 40 transfusions 
and does not differ for men and women. We were not able to find a plateau of sensitization 
and even beyond 40 units, there maybe be more alloimmunization taking place. More data 
is required to examine the risk of alloimmunization after more than 40th transfused unit. 
(addendum to figure 1)
ReFeRenCe liST
1. Abou-Elella AA, Camarillo TA, Allen MB, Barclay S, Pierce JA, Holland HK, Wingard JR, Bray RA, 
Rodey GE, Hillyer CD: Low incidence of red cell and HLA antibody formation by bone marrow 
transplant patients. Transfusion 1995; 35(11):931-935.
2. Ameen R, Al SS, Al-Bashir A: Red blood cell alloimmunization among sickle cell Kuwaiti Arab 
patients who received red blood cell transfusion. Transfusion 2009; 49(8):1649-1654.
3. Tormey CA, Fisk J, Stack G: Red blood cell alloantibody frequency, specificity, and properties in a 
population of male military veterans. Transfusion 2008; 48(10):2069-2076.
4. de La Rubia J, Arriaga F, Andreu R, Sanz G, Jimenez C, Vicente A, Carpio N, Marty ML, Sanz 
MA: Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC 
transplantation. Is ABO incompatibility a predisposing factor? Transfusion 2001; 41(1):106-110.
5. Higgins JM, Sloan SR: Stochastic modeling of human RBC alloimmunization: evidence for a distinct 
population of immunologic responders. Blood 2008; 112(6):2546-2553.
6. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M: Red cell alloimmunization in sickle cell 
disease. Br J Haematol 1986; 63(2):241-245.
7. Fluit CR, Kunst VA, Drenthe-Schonk AM: Incidence of red cell antibodies after multiple blood 
transfusion. Transfusion 1990; 30(6):532-535.
8. Blumberg N, Peck K, Ross K, Avila E: Immune response to chronic red blood cell transfusion. Vox 
Sang 1983; 44(4):212-217.
9. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS: Transfusion and 
alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 
76(7):1431-1437.
10. Schneeweiss S: A basic study design for expedited safety signal evaluation based on electronic 
healthcare data. Pharmacoepidemiol Drug Saf 2010; 19(8):858-868.
39
3
11. Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 
2003; 158(9):915-920.
12. Floss AM, Strauss RG, Goeken N, Knox L: Multiple transfusion fail to provoke antibodies against 
blood cell antigens in human infants. Transfusion 1986; 26(5):419-422.
13. Ludvigsen CW, Jr., Swanson JL, Thompson TR, McCullough J: The failure of neonates to form red 
blood cell alloantibodies in response to multiple transfusions. Am J Clin Pathol 1987; 87(2):250-251.
14. Strauss RG, Cordle DG, Quijana J, Goeken NE: Comparing alloimmunization in preterm infants after 
transfusion of fresh unmodified versus stored leukocyte-reduced red blood cells. J Pediatr Hematol 
Oncol 1999; 21(3):224-230.
15. Sarnaik S, Schornack J, Lusher JM: The incidence of development of irregular red cell antibodies in 
patients with sickle cell anemia. Transfusion 1986; 26(3):249-252.
16. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA: Multiple red cell transfusions and alloimmunization. 
Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch 
Pathol Lab Med 1995; 119(1):42-45.
17. Reisner EG, Kostyu DD, Phillips G, Walker C, Dawson DV: Alloantibody responses in multiply 
transfused sickle cell patients. Tissue Antigens 1987; 30(4):161-166.
18. Heddle NM, Soutar RL, O’Hoski PL, Singer J, McBride JA, Ali MA, Kelton JG: A prospective study 
to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J 
Haematol 1995; 91(4):1000-1005.
19. Redman M, Regan F, Contreras M: A prospective study of the incidence of red cell allo-immunisation 
following transfusion. Vox Sang 1996; 71(4):216-220.
20. Schonewille H, van de Watering LM, Brand A: Additional red blood cell alloantibodies after blood 
transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary 
measures? Transfusion 2006; 46(4):630-635.
21. Schonewille H, de Vries RR, Brand A: Alloimmune response after additional red blood cell antigen 
challenge in immunized hematooncology patients. Transfusion 2009; 49(3):453-457.
22. Schonewille H, Haak HL, van Zijl AM: RBC antibody persistence. Transfusion 2000; 40(9):1127-1131.
23. Dutch National Hemovigilance Office, The Hague. (2003) transfusion reaction in patients. TRIP 
Report 2008.
24. CBO Transfusion guidelines, (2004).www.cbo.nl, “Richtlijn Bloedtransfusie”.

CHAPTeR 4
eFFect oF storage oF red blood cells 
on alloImmunIzatIon
Transfusion 2013 Mar; (Epub)
Saurabh Zalpuri1,3 MD, MSc, Henk Schonewille1 PhD, Rutger Middelburg1,3 PhD, 
Leo van de Watering1 MD, PhD, Karen de Vooght4, James Zimring MD, PhD5, 
Johanna G. van der Bom1,2,3 MD, PhD, Jaap Jan Zwaginga1,3,6 MD, PhD
1 Center for Clinical Transfusion Research, Sanquin Blood supply, Leiden, Netherlands; 2 Department 
of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands; 3 Jon J van Rood 
center for Clinical Transfusion research, Leiden University Medical Center, Leiden, Netherlands; 
4 Blood transfusion, pediatric and point of care, Clinical chemistry and hematology laboratory, 
University Medical Center Utrecht, Utrecht, Netherlands; 5 Puget Sound Blood Center Research 
Institute, Seattle, WA, USA; 6 Department of Immuno- hematology and blood transfusion, Leiden 
University Medical Center, Leiden, Netherlands
Correspondence: Dr. J.J. Zwaginga; Leiden University Medical Center, Department of 
Immunohematology and Blood transfusion; Albinusdreef 2, Building 1, E3-Q; P.O. Box 9600, 
2300 RC Leiden, The Netherlands; t +31.71.5265129, f +31.71.5265267; j.j.zwaginga@lumc.nl




Red blood cells (RBCs) undergo changes during storage. Various studies have suggested a 
higher risk of adverse and often multi-factorial clinical outcomes associated with older stored 
RBCs. Our aim therefore was to examine if storage of transfused RBCs is also associated with 
the risk of RBC specific alloantibody formation. 
methods
A two-center retrospective case- referent study was performed where case patients and 
control subjects were sampled from all consecutive patients who had received their first 
and subsequent red blood transfusions in one of the two centers only. Cases were defined 
as patients who developed a first RBC alloantibody. Control subjects were patients without 
detectable RBC alloantibodies, who were matched to the case patients regarding number 
of RBC transfusions. Binary logistic regression analysis was used to examine the association 
between storage time of RBC and the occurrence of alloimmunization.
Results
A total of 144 cases and 286 controls were selected for our study, who had received a total 
5478 RBC units. Comparing patients receiving units stored shorter than a certain number 
of days versus older units (with various storage periods up to 4 weeks) did not reveal an 
association or a trend between alloimmunization risk and storage time categories.
interpretation
Our findings suggest that storage times of transfused RBCs between one and four weeks do 




Patients undergoing red blood cell (RBC) transfusions are exposed to non-self, donor 
red cell antigens, and as a result may develop antibodies to such foreign antigens. The 
alloimmunization risk is influenced by clinical1 and genetic predisposition2, as well as by the 
number of transfusions3. 
Red blood cells undergo various biochemical and biomechanical changes during storage, 
known collectively as the storage lesions. Such changes include membrane changes, changes 
in the vaso- dilatory capacity of micro-vessels due to NO release by free hemoglobin, 2, 3-DPG 
depletion and release of potassium4,5. Residual leucocytes and platelets are present, and the 
accumulation of released lipids, cytokines and histamine have been reported in suspension 
solution6,7. These lipids and micro-vesicles are biologically-active, with pro-inflammatory and 
pro-coagulant activity8. Currently, the clinical importance of these changes in stored RBCs is 
not clear, and there is much debate on the topic8-17.The definition of aged red cells varies in 
the available literature. Most often a storage time period of 14 days9-12 is used as a cut-off 
point to define older versus younger blood but this is arbitrarily based on the depletion of 
2,3 DPG in 2 weeks stored red cells4,13. Other storage lesion markers might well result in 
another differentiation of young vs. old blood. 
It was demonstrated that storage of RBC transfused in mice results in stronger 
immunization to one very immunogenic model antigen14. A similar phenomenon, however, 
was not observed for anti-D formation following Rhesus D incompatible transfusions in 
humans15. To clarify this issue for current transfusion practice storage times, we studied if the 
storage time of transfused RBCs was associated with the risk of alloantibody formation in a 
previously non-alloimmunized transfusion population. 
meTHodS
Study design and study population
A case referent study at the Leiden University Medical Center, Leiden and the University 
Medical Center Utrecht, Utrecht, in the Netherlands was performed. This study is part of an 
ongoing study on Risk Factor for Alloimmunization after red blood Cell Transfusions (R-FACT). 
The full protocol of the study has been published previously16. The study was approved by the 
ethics committees of both participating hospitals. 
The source population consisted of all not previously transfused, non-alloimmunized 
patients who had received their first RBC transfusion, including at least one pre- and post-
transfusion antibody screening, at the same study center. The study period was January 2005 
to December 2010 at Leiden University Medical Center and January 2006 to December 2011 
at University Medical Center Utrecht, Utrecht. Cases were all patients in the cohort with a 
first time ever RBC alloantibody. For each case two controls were sampled and matched to 
case patients based on the total number of red cell transfusions received. This was done 
following the “risk-set” sampling strategy from the total transfusion cohort, who were at 
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risk (i.e., had at least received the same number of RBC units) of becoming a case at the time 
the case was diagnosed22. 
Children were excluded, because in the participating hospitals children routinely received 
RBC stored for ≤7 days, as a matter of transfusion policy. 
Storage time was categorized in weekly periods up to 4 weeks for the analysis.
implicated Period
An “implicated period” or a “clinical risk period for alloimmunization” was defined for case 
and control patients as the period in which a transfusion most likely caused the observed 
primary alloimmunization. This implicated period was the time (in days) between the last 
transfusion before a first ever positive alloantibody screen and 30 days earlier16. To optimize 
the likelihood that our cases were primary immunizations, and not secondary booster 
immunizations, we considered an alloimmune response to need a minimum “lag period” of 
7 days between the first finding of the antibody and the last preceding transfusion. As part 
of a study on clinical risk factors, a similar implicating period was selected for the controls16. 
(details presented in the published R-FACT study protocol16)
Red blood Cells and First time formed RbC alloantibody
Routinely transfused red blood cells in the Netherlands are in SAGM, pre-storage 
leukoreduced, not irradiated. RBC alloantibodies were defined as warm reacting clinically 
significant antibodies (C, E, c, e, Cw, K, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub, M, N, S and s), 
screened for using a three cell panel including an indirect antiglobulin test (LISS Diamed ID 
gel system) and subsequently identified by a standard 11 cell panel using the same technique. 
All patients were routinely screened for alloantibodies before transfusions. If transfusions 
were given at subsequent days, the maximum interval between screens was 72 hours. 
data acquisition
Transfusion dates and dates of donation of every RBC unit received, dates and results of the 
antibody investigations, patients’ dates of birth, gender and ward of hospitalization were 
gathered from the hospitals’ electronic laboratory information management systems.
data Analysis
Binary logistic regression analysis was used to examine the association between storage time 
of RBC and the occurrence of alloimmunization. Analysis was conducted based on various 
cut-off days for younger and older stored RBC units. Patients receiving on average fresher 
RBC unites were compared to patients receiving on average older units. In addition, patients 
who had received only younger (fresher) stored RBC units were compared to patients who 
received only older RBC units, to exclude any effect of the mixed stored (a combination of 
young and old blood units) RBC units17.
All odds ratios (ORs, 95% confidence interval, CI) were corrected for the number of 
transfusions for which the cases and controls were matched. We presented adjusted ORs, 
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adjusted for possible determinants that could have confounded the association, independent 
of their statistical significance in the univariate analysis.
Confounders
We corrected for the number of transfusions in the implicating period (or, clinical risk period) 
since RBC units stored for a longer period have a tendency to be given out to patients 
requiring low numbers of units. This is due to the often practiced ‘first in, first out’ inventory 
management policies. Patients with indications for massive transfusions usually receive shorter 
stored RBC units, as a result of “first in, first out” inventory management policies. Additional 
categorical variables were patient age, sex and clinical ward of transfusion requirement (with 
acute requirements like surgical wards vs non-acute requirements like hematology wards), 
hospital and year (2005-2011) of donation of the transfused products. The latter two can 
be regarded as possible indicators of changes in blood collection, manipulation and different 
local transfusion strategies, if any. 
ReSulTS
Population Characteristics
During the study period, 17767 patients received first ever RBC transfusion at our study 
centers and 156 formed clinically relevant RBC alloantibodies.
The study population initially comprised of 468 patients (156 cases, 312 controls). After 
excluding 38 children, the remaining 144 cases and 286 controls had received a median of 
9 RBC units in the study period and median 4 units in the implicated period. The distribution 
of age, sex, mean storage time per RBC unit and ward of hospitalization in cases and controls 
are presented in table 1. The median storage time of transfused RBC units was 16 days. 
Table 1. Characteristics of RBC alloimmunization case and control patients
Characteristics Case patients Control patients
Number of patients 144 286
Males (n)





Age (mean, standard deviation) 57.5 (18.3) 57.5 (18.2)
Total number of RBC units 





Total number of RBC units in implicated period





Median storage time in implicated period (in days) 





Patients in wards with acute RBC requirements, n (%) 67 (47) 147 (51)
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Storage time and risk of alloimmunization
The majority of case patients (50%) were present in the average storage time category of day 
15-21 days, (week 3) and was chosen as the reference group, in order to establish a robust 
comparison group. Patients receiving on average stored blood less than 2 weeks old; and patients 
receiving on average stored blood more than 3 weeks old compared to week 3 had adjusted ORs 
for alloimmunization of 1.05 (95% CI 0.6-1.8) and 0.9 (95% CI 0.7-1.3) respectively. (Table 2)
Table 2. Association between storage times considered as the average storage time per patient, 





















* Odds ratio adjusted for number of matched transfusions 
** Odds ratio adjusted for number of matched transfusions, sex, ward of hospitalization, hospital, 
patient age and transfusions received in implicated period 
Table 3. Association between average storage time of RBC unit per patient and risk of 
alloimmunization: Comparison of average blood older than 14 days to average blood younger than 







82 Crude OR * Adjusted OR **
































* Odds ratio adjusted for number of matched transfusions 
** Odds ratio adjusted for number of matched transfusions, sex, ward of hospitalization, hospital, 
patient age and transfusions received in implicated period
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Next, patients transfused with units with average storage times more than 14 days up to 
more than 21 days were compared to patients with transfused units with average storage 
times less than 14 days and observed no differences, with adjusted ORs in the ranges of 
0.7-0.9 (95% CI ranges 0.4-1.7) (Table 3)
Lastly, to try and disentangle the effect of mixed blood (fresher and older stored transfused 
units) and compare only old versus only fresh transfused blood, patients receiving only RBC 
units stored for less than 14 days were compared with patients receiving RBC units stored 
only longer than 14 days up to only longer than 21 days and observed no clear association. 
Only in patients receiving exclusively units stored for more than 21 days as compared to less 
than 14 days, an adjusted OR of 0.4 (95% CI 0.1-1.01) was found.(Table 4) 
Table 4. Association between storage time of RBC units per patient and risk of alloimmunization: 
Comparison of patients receiving only more than 14 days stored blood to patients receiving only less 
than 14 days stored blood
“X” days 
vs.




51 Crude OR * Adjusted OR **
































* Odds ratio adjusted for number of matched transfusions 
** Odds ratio adjusted for number of matched transfusions, sex, ward of hospitalization, hospital, 
patient age and transfusions received in implicated period 
diSCuSSion
In our case-referent study in a previously non-transfused, non-immunized population, storage 
times of RBC units were not associated with the post-transfusion risk of alloimmunization 
against clinically significant RBC antigens. We did observe an association between storage 
time and alloimmunization at the >21 days versus ≤14 days comparison cut-off; however, 
given our study size, this could be a chance finding.
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To our knowledge, this is the first study examining the effect of clinically relevant storage 
times of red blood cells and clinically relevant alloimmunization against non-AB and non 
rhesus D RBC antigens that patients normally are not matched for. 
The association between the receipt of older stored red cells and other adverse clinical 
outcomes has been studied before10,11,20,21. Most of the available literature has suggested 
adverse effects of the older stored red cells on clinical endpoints such as post-operative 
infections and complications, multi-organ failure and mortality. There is no agreement, 
however, on whether these associations are causal4.
By excluding children from our study, a source of confounding by indication was avoided, 
since children were routinely transfused (at both the study centers) with blood stored for less 
than 7 days. In addition, we adjusted for numerous variables in our study that could have had 
an influence on the storage time of RBC as well as the risk of alloimmunization. 
Failure to detect case patients in our study cohort (measurement bias) might be due 
to the variable follow-up in post transfusion antibody screening. The study design with 
“risk- set” sampling of our controls from the source cohort, we feel prevents this possible 
measurement bias from affecting our exposure (storage time of red cells) distribution in the 
different comparison groups20. Furthermore, we cannot unequivocally rule out secondary 
immunizations. However, by including only pre-transfusion non-alloimmunized patients as 
well as introducing the 7 day lag period between first antibody detection and the date of 
the last preceding transfusion to define the implicated transfusion period, we feel to have 
efficiently minimized booster reactions. A relative limitation of the study was that there were 
very few patients who received only red cells stored for less than 7 days or only red cells 
stored for more than 28 days. The effect estimates of these extreme ends of storage time on 
alloimmunization were therefore not reliable (wide 95% CIs, data not shown). The inability to 
obtain such extreme end data – although of conceptual value – seems to indicate their small 
relevance for day to day practice. 
Our 95% confidence intervals clearly justify our conclusions for case and control patients 
who received RBCs within the storage time ranges of 7-28 days. This storage time range is 
a reflection of the average RBC storage time range with which 95% of patients in our study 
centers are transfused. 
A hypothesis which could be considered for our observed lack of association with the 
older stored RBC units (as well as fresher RBC units) could be that two different and opposing 
“heightened” periods of danger may exist – 1) increasing immunogenicity by leukocyte 
activity in fresher units that decreases with storage, and 2) immunogenicity by accumulation 
of cytokines, lipids, histamines and micro-vesicles that increases with storage; where these 
might largely cancel out each other’s effect. 
So far murine studies have shown that exclusive transfusion of older units of red cells 
(expressing a model antigen consisting of hen egg lysozyme fused to ovalbumin fused to 
human Duffyb (HOD antigen) resulted in a stronger antibody response than fresh units. 
Moreover, the co-incident transfusion of fresh RBCs dampened the immunogenicity of the 
stored RBCs17. It is worth noting that these findings involved the height of antibody titers 
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against a very immunogenic antigen causing universal immunization. The non-AB, non-D 
RBC antigens in humans that are not matched for in transfusion practice, are usually much 
less immunogenic. RBC alloimmunization for non AB, non rhesus D antigens in humans, as a 
function of RBC storage, therefore can only be studied in very large observational datasets. 
With this, we have to accept that the routine assays around these immunizations do not 
include validated antibody titer determinations. The immunization frequencies in humans, 
as in our study, therefore cannot be directly compared with results on antibody titers in 
universally immunized mice. Additionally, alloimmunogenicity in the murine studies did not 
substantially increase until a point in storage that can be considered to be equivalent to 42 
days of human RBC storage. 
A potential important modulator for immunization that studies of this type neither are able 
to study involve donor RBC and patient factors that determine RBC survival in the patient’s 
circulation. This post transfusion survival23 as ‘biological age’ of a given unit might likely be 
more important for alloimmunization than the “chronological (storage) age”. Currently, as 
RBC survival studies are not routinely done in clinical studies, this issue cannot be assessed 
with normal laboratory practice.
In conclusion, our patient population, study design and storage time ranges showed that 
so far, there is no evidence that pre-transfusion storage time (within the ranges of 7-28 days) 
of red blood cells modulates the risk of alloimmunization. Some indication of a protective 
effect of older RBC (older than >21 days) was seen but given the study size, this may well be 
a chance association.
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Exposure to allogenic red blood cells may lead to formation of antibodies against non-self 
antigens in transfused patients. While alloimmunization rates are known to increase with the 
number of transfusions, the transfusion course in patients can vary from receiving multiple 
units during a single transfusion event or getting them dispersed over a long(er) period. In the 
present study we compared the immunization risk between different transfusion intensities.
methods
An incident new-user cohort study was conducted among consecutive transfused patients 
at two university medical centers. Eligible were all patients who received their first red blood 
cell transfusion within the study period from January 2005 to December 2011. Intensive 
transfusions were defined as ≥5, ≥10 and ≥20 RBC units within 48 hours. Alloimmunization 
hazard rates (HR), comparing patients receiving intensive transfusions to patients never 
receiving intensive transfusions were estimated. 
Results
The study cohort comprised of 5812 patients who had received a median of 7 (Inter Quartile 
Range=4, 12) units. RBC alloantibodies were formed by 156 patients. The adjusted Cox-
regression hazard rates for alloimmunization, with number of units as the time covariate and 
adjusted for patient age, sex and the follow up time after first transfusion, ranged from 0.8 
to 1.2 (95% ranges CI- 0.4 to 2.6). 
Conclusion
The occurrence of RBC alloimmunization in patients receiving intensive transfusions did not 




Exposure to allogenic red blood cells (RBC) may lead to formation of antibodies against 
non-self antigens in transfused patients. Besides genetic predisposition1 and clinical immune 
modulating (e.g. medications or infection) factors2, the risk of alloantibody formation is also 
influenced by the number of transfused RBC units3,4. 
Intensive (or massive) transfusions refer to a large amount of transfusions in a short 
period of time, and there is a lack of general consensus5,6 in defining massive or intensive 
transfusions in the literature. Massive transfusions have been demonstrated to be associated 
with systemic inflammatory response syndrome7,8; higher rate of post-operative infections9 
and prolonged ICU stays9. 
Most transfusion recipients fail to react to donor alloantigens after multiple transfusions 
which may depend on antigen dosage but also on immune modulation factors of tolerance 
induction or otherwise. In healthy Rh D negative donors, a high (80-95%) anti-D rate after 
deliberate immunization against very low doses of D antigen has been demonstrated.10,11 
On the other hand, much lower (15%) rates of D immunization have been found in acutely 
transfused patients undergoing liver and heart12 transplants and even an inverse correlation 
between number of D-incompatible transfusions and anti D formation was reported13. 
These examples underline that the minimum doses of alloantigens (or transfusions), the 
number of doses and the interval between doses may be important determinants of 
immune response.
Noting that the impact of intensive transfusions on alloimmunization is surprisingly 
unknown, we examined the association of transfusion intensity and the risk of clinically 
relevant RBC alloantibody formation in a previously non-transfused, non-alloimmunized 
cohort. 
meTHodS
Study design and study population
An incident new user cohort study among consecutive transfused patients at the Leiden 
University Medical Center (LUMC) and the University Medical Center Utrecht (UMCU), in 
the Netherlands was conducted. The study period was January 2005 to December 2010 at 
Leiden University Medical Center and January 2006 to December 2011 at University Medical 
Center Utrecht, Utrecht. Eligible patients were all patients who received their first red blood 
cell transfusion within the study period in our study centers. We could not exclude patients 
with previous transfusion history in other hospitals, due to absence of such information in 
the transfusion records of the study centers. To minimize inclusion of previous transfusion 
recipients, transfusions were included when preceded by a negative antibody screen and 
followed by a post transfusion antibody screen. 
With this cohort design, the transfused population was followed up until the event 
(alloantibody formation), or the last negative antibody screen. 
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red blood cells and first time formed rbc alloantibody
Routinely transfused RBC in the Netherlands are in SAGM, pre-storage leukoreduced. RBC 
alloantibodies were defined as warm reacting clinically significant antibodies (C, E, c, e, Cw, 
K, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub, M, S and s), first screened for using a three cell panel 
using an indirect antiglobulin test (LISS Diamed ID gel system) and subsequently identified 
by a standard 11 cell panel using the same technique. Alloantibodies of other specificities 
other than those mentioned, as well as cold reacting alloantibodies were ignored. The reason 
was that the antibodies which were included were measured routinely at the study centers 
before every transfusion, by a standard 3 cell panel. Other antibodies might be present, but 
they were not measured as a routine clinical practice, hence go undetected. Since it would be 
invalid to present data on such antibodies that were not measured in all patients, we decided 
to only study alloantibodies present on a standard 3 cell panel used for antibody detection.
All patients were routinely screened for alloantibodies before transfusions. If transfusions 
were given at subsequent days, the maximum interval between screens was 72 hours. 
Same antibody screening methods were employed during the total study period.
transfusion intensity (or Intensive transfusions)
Transfusion intensity was defined as the number of units transfused per transfusion event 
within 48 hours. This 48 hour period was chosen to cover the overnight (past-midnight) 
transfusions from one calendar date to the next. To study the effect on alloimmunization rate 
in patients receiving multiple units at the same time versus multiple units over a longer period 
(non-intensive transfusions), calculations were performed with increasing cut-off values for 
intensive transfusion, i.e. ≥5, ≥10 and ≥20 RBC units within 48 hours, respectively. The study 
population comprised of three types of patients based on their transfusion patterns:
1. Patients who received intensive transfusions during their first transfusion event.
2. Patients who received intensive transfusions during a later time point in their transfusion 
history. 
3. Patients who never received intensive transfusions. 
To analyze the influence of intensive transfusions during a single transfusion event on 
alloimmunization rate, and exclude any influence of previous transfusion events on a later 
intensive transfusion event, patients who received the defined RBC units (≥5, ≥10 and ≥20) 
during their first event (type 1) were compared to those without intensive transfusions. For 
reasons of clarity we decided to concentrate on the effect of intensive transfusions only during 
the first transfusion, independent of what happens afterwards. Patients who received intensive 
transfusions during a later transfusion time point (type 2) were followed until that intensive 
transfusion event (excluding the event itself) and their transfusion information up until that 
time point was combined with patients who never had intensive transfusions (type 3).
Follow up time
A transfusion at our two study centers is routinely preceded with an RBC antibody screen, as a 
matter of transfusion practice. Therefore, follow up time for antibody formers was calculated 
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as the time between their first transfusion and first ever alloantibody positive screen and for 
non alloantibody formers, the time between their first and the last transfusion, preceded by 
a negative antibody screen. From the total cohort, only those patients were selected who had 
a minimum follow up time of 7 days. We hypothesized that a minimum period of 7 days after 
a transfusion is required to mount an antibody response while earlier detection of antibodies 
more likely indicates a booster (previous) immunization.
data Analyses 
Baseline characteristics were presented as medians with inter-quartile range (IQR).
Kaplan Meier survival analysis with number of transfusions as the time axis was used to 
describe alloimmunization incidences.
Cox regression analysis was performed to estimate the hazard ratios (HR) of 
alloimmunization with number of transfusions as the time covariate. Crude and adjusted 
HR, adjusted for patient age (<= 25, 26 to 50, 51 to 75 and > 75 years), sex and the follow 
up time after first transfusion (adjusted as a continuous and a quadratic expression), were 
presented with 95% confidence intervals.
We conducted a sensitivity observed/ expected analysis. The observed number of 
antibodies in the intensive transfused group was known. To calculate an expected number of 
antibodies in this intensive group, were they hypothetically to be non-intensively transfused, 
we first calculated a cumulative incidence of antibody formation in the non-intensively 
transfused group (with standard errors). This cumulative incidence (from the non-intensive 
group) was used to calculate an expected cumulative incidence of antibody formation in the 
intensively transfused group. Thus, an expected number of antibodies was obtained in the 
intensively transfused group, if they were to be transfused with the same number of RBC 
units, but in a non-intensive manner. With the observed (actual) and the expected number 
of antibodies in the intensive group, we calculated a risk ratio and using bootstrapping 
methods, a 95% confidence interval.
ReSulTS
Characteristics of the study population
The study population comprised of 5812 patients of which 156 (2.8%) formed clinically 
relevant red cell alloantibodies. The median age of the study population was 55 years (IQR = 
25, 68), comprising of 56.4% males receiving a median of 7 (IQR = 4, 12) transfusions. The 
median follow-up period was 66 days (IQR = 22, 245), and almost twice as long in antibody 
formers as compared to non-antibody formers (Table 1). 
Twelve patients in the intensively transfused group formed 15 antibodies, compared to 
142 patients in the non-intensively transfused group forming 184 antibodies. The antibodies 
formed per patient in intensively and non-intensively transfused patients were 1.25 and 1.30 
respectively.
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Characteristics of intensively transfused (≥ 10 units) and non-intensively 
transfused population
After excluding patients with less than 7 days of follow up, 5746 patients remained in the 
cohort out of which 183 (3.2%) were intensively transfused and 12 (6.5%) of them formed 
alloantibodies as compared to 142 (2.6%) of non-intensively transfused patients. 
This cohort of 5746 patients (with 67.2% males) received 7 median units (IQR = 4, 12). 
The intensively transfused among this cohort received almost 3 times as many median units 
Table 1. Characteristics of antibody formers and non-antibody formers in the cohort*
Antibody formers Non-antibody formers
Number of patients 156 5656
Male/ Female ratio 1.3 1.3
Age (years) 59 (38, 70) 55 (24, 68)
Follow- up in days 123 (24, 314) 65 (22, 244)
Transfused units 6 (2, 10) 7 (4, 13)
*Data are presented as medians and Inter Quartile Range
Table 2. Characteristics of Intensively transfused (≥ 10) and non-Intensively transfused patients*
Intensively transfused Non-Intensively transfused
Number of patients 183 5563
Antibody formers (%) 12 (6.5%) 142 (2.6%)
Male/ Female ratio 1.9 1.3
Age (years) 60 (44, 71) 55 (23, 68)
Follow-up in days 23 (13, 90) 68 (22, 248)
Transfused units 20 (15, 32) 7 (4, 11)
*Data are presented as medians and Inter Quartile Range
Table 3. Intensively transfused patients and their indications for intensive (≥ 10) transfusions




Cardio- thoracic surgery 66 (36.1) 6 (9.1)
Transplants 16 (8.7) 1 (6.3)
Surgery, other* 69 (37.2) 1 (1.4)
Trauma 31 (16.9) 4 (12.9)
* emergency, neuro, spinal, vascular and abdominal surgeries; fluxus- post partum
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than the non-intensive group (Table 2) and the median follow-up period was 23 days (IQR 
= 13, 90), almost 3 times shorter than in the non-intensive group, 7 (IQR = 4, 11). Table 3 
presents the indications for transfusion among the intensively transfused patients (indication 
for intensive transfusion was missing for one patient).
Intensive transfusion and risk of alloimmunization
The Kaplan-Meier analysis showed no difference in the risk of alloimmunization between the 
intensively transfused group (≥ 10 units) as compared to the non-intensive group (Figure 1). 
Similar Kaplan-Meier analyses were done for the other cut-off values of intensive transfusions 
(i.e. ≥5 and ≥20 units within 48 hours) and no difference in alloimmunization risk was 
observed (Figures 1 and 2 respectively, shown in appendix). 
 
 89
Table 4: Intensive and non-Intensive transfusions and the risk of alloimmunization 
(HR) using the number of units as the time covariate** 
 
*Adjusted for sex, age and follow up time after first transfusion.  
**The intensive group receiving ≥5 u its compris  of 550 patients with 5.5% antibody formers, the 
numbers for the ≥20 group were 45 with 8.8% antibody formers. 
 
 
Figure 1: Kaplan Meier estimate of alloimmunization in intensively transfused (≥10 units) 
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Figure 1. Kaplan Meier estimate of alloimmunization in intensively transfused (≥10 units) and non-
intensively transfused patients 
Number of patients remaining at transfusion number:
Transfusions à 0 20 40
Intensive 182 94 24
Non-Intensive 1817 602 151
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The crude and adjusted Cox-regression hazard ratios, with number of transfusions as the 
time covariate revealed no differences in alloimmunization risk in the intensively transfused 
group as compared to the non-intensively transfused group regardless of cut-off values for 
intensive transfusions (Table 4).
Table 4. Intensive and non-Intensive transfusions and the risk of alloimmunization (HR) using the 
number of units as the time covariate**
Intensive 
transfusion
Hazard Ratio (95% CI) 
≥5 units                             ≥10 units                            ≥20 units















* Adjusted for sex, age and follow up time after first transfusion. 
** The intensive group receiving ≥5 units comprised of 550 patients with 5.5% antibody formers, 
the numbers for the ≥20 group were 45 with 8.8% antibody formers.
Sensitivity analysis
The observed number of antibodies in the intensive group (≥ 10 units) was 12. An expected 
9.2 antibodies were calculated in this group, giving a risk ratio of 1.3 (95% CI 0.7-2.1). The 
confidence intervals were estimated after 10,000 bootstrapping runs. The risk ratios were 
similar in other intensive transfusion categories (≥5 and ≥20 units).
diSCuSSion
In our study, no statistically significant difference in the risk of alloimmunization in intensively 
transfused patients and non-intensively transfused patients was found (stratified on the 
number of transfusions and using three cut-off values for intensive transfusions). 
Strength of our study was the incident new user cohort study design, which avoids 
inclusion of prevalent users in the study cohort14. This study design and its data collection 
approach allowed a prospective follow up of previously non-transfused and non-immunized 
patients during subsequent transfusions up to the appearance of a first alloantibody. 
Although all the patients with a previous transfusion history in our study centers prior to 
2005 were excluded, the possibility of previous transfusions in a different hospital cannot 
be ruled out entirely. Secondary immune responses may have occurred. We, however, do 
not expect this to affect our study findings. There is no reason to believe that patients with 
unknown previous transfusions and with unknown previous antibodies are more likely to get 
a massive transfusion.
The difference in follow up times between intensively transfused (median 23 days) and 
no intensively transfused (median 68 days) can be attributed the fact that the intensively 
transfused patients were censored right after their intensive transfusion events, (hence 
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the shorter follow up time) as compared to non- intensively transfused patients who were 
followed up until the end of the study period.
This cohort, in our opinion, is a good representation of a general transfused population. 
In the absence of a clear consensus on the definition of a massive transfusion event, three 
definitions were used to study the effect of intensity of transfused units on the risk of 
alloimmunization.
In addition to the Cox regression analysis, we performed an observed/ expected analysis 
to verify the results from Cox models. The Cox model calculates “instantaneous” antibody 
incidence, censoring a patient as soon as an antibody is formed. Intensive transfused patients 
receive many transfusions without a gap in between transfusions to measure antibodies after 
every transfusion, which makes it difficult to pin-point the exact transfusion after which an 
antibody was formed. This may bias the Cox estimate. An observed/ expected analysis is 
based on cumulative incidence, hence less sensitive to the potential mis-estimation by the 
Cox model. 
In our approach, subsequent non-intensive transfusions after the intensive transfusion 
event in the intensively transfused group were included. This might affect the immunization 
risk estimate of the intensive transfusion event. However, there is no a priori reason to believe 
that for example, the 20th transfusion after the intensive episode carries a different risk of 
alloimmunization than the same 20th transfusion in the non-intensively transfused group. 
We furthermore acknowledge the possible presence of immunologic non-responders to 
alloantigens in our study cohort, as postulated in other studies15,16. This is not regarded as 
a source of confounding in our study because it cannot be envisioned that being a (non-) 
responder is related to receiving intensive or non-intensive transfusions. Their distribution in 
the intensive and non-intensive transfused group, thus, is independent of being a responder 
or a non-responder.
So far, the effect of intensity of blood transfusions on alloimmunization against 
clinically relevant (non Rh D) red cell antibodies has not been reported. Intensive or massive 
transfusion, and more specifically, the circumstances in which intensive transfusions are 
usually administered namely, major thoracic surgeries, surgeries post- trauma etc. combined 
with medications and the administration of a massive load of non-self transfused antigens, 
are likely to modulate the immune system and with it possibly responses to non-self antigens. 
In this respect, the immunological “danger model” theory on one hand proposes that an 
immune response may be exaggerated by not only the non-self antigen but also by the extent 
of trauma/ tissue damage17,18. The alloantigens in the transfused blood together with the 
danger signals from the damaged tissue collaborate to trigger an immunologic alarm and 
mount an immune response. In line with this, a chronic inflammatory state which for instance 
accompanies sickle cell disease appears to enhance alloimmunization19. Moreover, previous 
febrile reaction/ inflammatory response to platelets was associated with higher risk of RBC 
alloimmunization20. Finally, murine studies confirm that some pro- inflammatory stimuli21 and 
increased inflammatory state22 enhances humoral immunization to transfused alloantigens. 
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On the other hand, it has been suggested that the conditions surrounding acute 
transfusions lead to suppression of the immune system. Trauma to the tissue induced by 
surgery is known to be immuno-suppressive23. Trauma associated transfusions can lead 
to micro-chimerism, and these individuals undergo global immuno-suppression24 that 
predisposes these post trauma transfused patients to donor leucocytes tolerance as well as 
diminished alloantigenic responses24,25. Medications, with corticosteroids being an evident 
example, administered in the setting of massive transfusion can also suppress patient’s 
immune response12. Donor leucocytes may both activate or attenuate the recipient’s immune 
system with beneficial tolerance as shown in renal grafts26 as well as deleterious effects like 
increase in infections27.
The dose (intensity) of red blood cells in our study was categorized in to three categories 
but it is worth noting that the dose of exposure to a particular antigen itself could not be 
quantified in our study. The amount of antigen being taken up by the immune system itself 
was another variable which was unquantifiable in our observational study. An intensively 
transfused patient might haemorrhage a lot of blood while being transfused, and may end 
up with the same amount of antigen to the immune system as a non-intensively transfused 
patient. This antigen dose related questions might be relevant and should be addressed in 
future research on this theme. 
Given our study population, study design and intensive transfusion definitions, we did 
not find an association between intensively and non-intensively transfused patients, and the 
risk of alloimmunization. Future research is warranted to study the clinical risk factors of 
alloimmunization. 
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Figure 1: Kaplan Meier estimate of alloimmunization in intensively transfused (≥5 units) and non-
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Figure 2: Kaplan Meier estimate of alloimmunization in intensively transfused (≥20 units) and non-




Table 1: Intensive* and non-Intensive transfusions and the risk of alloimmunization (HR) using the 
number of units as the time covariate; using =>14, =>21 and => 28 days minimum follow up cut-
offs 
 
Minimum follow up time in days 
<= 14 (HR**, 95% CI) <=21 (HR**, 95% CI) <=28 (HR**, 95% CI) 
1.2 (0.6- 2.4) 1.3 (0.6- 2.7) 1.2 (0.5- 2.6) 
 
* Intensive transfusion: ≥10 units 
**Adjusted for sex, age and follow up time after first transfusion. 
Log rank p- value= 0.8 
 
Table 1. Intensive* and non-Intensive transfusions and the risk of alloimmunization (HR) using the 
number of units as the time covariate; using =>14, =>21 and => 28 days minimum follow up cut-offs
Minimum follow up time in days
<= 14 (HR**, 95% CI) <=21 (HR**, 95% CI) <=28 (HR**, 95% CI)
1.2 (0.6-2.4) 1.3 (0.6-2.7) (0.5-2.6)
* Intensive transfusi n: ≥10 units
** Adjusted for sex, age and follow up time after first transfusion.
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Patients receiving red blood cell transfusions are at risk of developing alloantibodies against 
donor red cell antigens. The risk of alloimmunization is dependent on the number of units 
administered and patient’s genetic predisposition, but has also been suggested to be modulated 
by a patient’s clinical profile. Our aim was to examine whether immunosuppressants suppress 
the development of clinically relevant RBC antibodies. 
methods
A two-center retrospective case- referent study was performed where case patients and control 
patients were sampled from all consecutive patients (17,750 patients) who had received 
their first and subsequent red cell transfusions in a five year period in the study centers. 
Cases were all patients with a first detected RBC alloantibody preceded by negative antibody 
screens. Control patients were two-to-one matched to the case patients on the number of 
RBC transfusions. Logistic regression analysis was used to examine the association between 
immunosuppressant exposure and the subsequent occurrence of RBC alloimmunization.
Results
Among the total study population, 98 patients received immunosuppressive therapy, with 
46 patients receiving only corticosteroids, 16 receiving only other immunosuppressants and 
36 receiving both. A total of 156 case patients and 312 control patients in the study received 
a median of 6 transfusions (interquartile ranges 3, 11). The incidence of alloimmunization 
among patients using immunosuppressants was lower than among other patients receiving 
red blood cells, adjusted relative rate (RR) 0.46 (confidence interval, CI 0.23-0.89). 
interpretation





Patients receiving red blood cell transfusions are at risk of developing alloantibodies against 
donor red blood cell antigens1. Alloimmunization against clinically relevant red cell antigens 
can cause serious complications like acute and delayed hemolytic transfusion reactions. In 
light of this, it becomes important to study the risk factors associated with alloimmunization 
in detail, in order to predict which patients are most vulnerable to alloimmunization; and thus 
they may be considered for more extended matched red blood cell transfusions to prevent 
alloimmunization. On the other hand identifying clinical factors protecting patients against 
alloimmunization would be equally important.
The risk of alloimmunization is dependent on the number of red cell units administered1. 
The extent of alloimmunization has been studied in various populations with the incidence of 
alloimmunization increasing with the number of units, ranging from 7%1 (after 40 transfused 
units) to 13%2 (estimated ) in a general transfused population. The risk of alloimmunization 
is also determined by a patient’s genetic predisposition to form an immune response to 
these non-self antigens3. In addition, it has been suggested that a patient’s clinical condition4 
is associated with modulation of the alloimmunization risk. Immunosuppressive therapy 
could be of particular importance in this respect, because red blood cell transfusions and 
immunosuppressive therapy often coincide in intensive care, trauma, active autoimmune 
disorder, cancer and organ transplant patients. 
The use of immunosuppressants among a general transfused population and its effect on 
the risk of clinically relevant RBC alloimmunization, however, has not been reported and was 
the purpose of this study.
meTHodS
design and study population
A matched case-referent study was performed at two study centers- Leiden University 
Medical Center, Leiden and University Medical Center Utrecht, Utrecht, in the Netherlands. 
Details of our case- referent study design have been previously described5. In short, the 
source population comprised of all previously non-transfused, non-alloimmunized patients 
who received their first RBC transfusion at one of the study centers. The study period was 
January 2005 to December 2010 at Leiden University Medical Center and January 2006 to 
December 2011 at University Medical Center Utrecht, Utrecht. 
Case patients were patients with first time detected clinically relevant red cell antibodies 
and control patients were patients who did not have clinical red cell antibodies after the 
same number of transfusions as the matched case. The control sampling was conducted on 
the principles of a risk-set sampling strategy6, e.g. for any given case (with N units up until 
alloantibody formation), two control patients with at least the same number of units were 
randomly selected from the source population (figure 1). Control patients were then matched 
to case patients on N number of units (figure 1). Case and control patients were also matched 
on the study center5.
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The transfusion policy in the study centers was as follows: 1) routinely transfused RBC 
concentrates were in SAGM and pre-storage leukoreduced and 2) all patients were routinely 
screened for alloantibodies before transfusion which was repeated at least every 72 hours, if 
further transfusions were required. 
Clinical risk period (implicated Period) of alloimmunization
We first set out to define an ‘immunization risk’ period preceding the antibody finding in order 
to identify the concurrent clinical conditions that in combination with an antigen mismatched 
transfused unit (implicated unit) could have led to alloimmunization. We measured all the 
study variables within this clinical risk period.
For the case patients, this risk period5,7 was defined as a 30 day period preceding the 
date of the transfusion immediately before) the first positive alloantibody screen5. We chose 
the risk period not to include the week just before the positive screen to “give” antibodies 
at least one week to develop. The risk period definition is illustrated in Figure 1. A similar 
clinical risk period was defined for the control patients, as the period of 30 days preceding 
the transfusion, at which case and control patients had been matched (figure 1).
Using the above defined method to pick a clinical risk period (the so called implicated 
period) of alloimmunization, we found in the majority (88%) of our case patients at least 
one transfusion with the mismatched antigen in the risk period immediately preceding the 
antibody identification. For the remainder of case patients, we looked further back into their 
transfusion history to identify the mismatched antigen transfusion unit and re-defined the 
implicated period as per the above mentioned5 definition of implicated period, around that 
particular mismatched transfusion.
Figure 1. Control patient selection and Clinical risk period*
* The chronological order from case patient identification to clinical risk period definition is marked 
from number 1 to 5.
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Figure 1: Control patient selection and Clinical risk period* 
 
 
* The chronological order from case patient identification to clinical risk period definition is marked from 
number 1 to 5. 
  
Table 1: Immunosuppressive medication use among total study population of 468 
patients 
 
Immunosuppressive medications (98 patients) 
Number of patients (%) 
Using corticosteroids 
 
Prednis lone 50 (51) 
Prednisone 15 (15) 
Dexamethasone 12 (12) 
Triamcinolone 5 (5) 
Hydrocortisone 4 (4) 
Methylprednisolone 1 (1) 
Betamethaso e 1 (1) 
 
Using other immunosuppressants 
 
Cyclosporine 34 (34) 
Mycofenolaat mofetil 22 (23) 
Azathioprine 3 (3) 
Lenalidomide 2 (2) 
Everolimus 1 (1) 
Methotrexat 1 (1) 
Thalidomide 1 (1) 
2. Population at risk for being a case
3. Control one 3. Control two
1. Case
antibody
5. Implicated period of Clinical risk period 





transfusions one two three four five
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There were 20 cases with antibodies like Fya, Jka, M for whom an antigen mismatched 
red blood cell unit could not be confirmed. This is because the donor red cell units are usually 
not typed for antigens except for ABO, D, other rhesus (C, E, c, e) and K antigens.
First time formed clinically relevant red cell alloantibodies
Red cell alloantibodies were defined as warm reacting clinically significant antibodies (C, E, c, 
e, Cw, K, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub, M, S and s), and were screened for using a three 
cell panel including an indirect antiglobulin test (LISS Diamed ID gel system) throughout the 
study period. Positive screening in the three cell panel led to subsequent identification of the 
antibody or antibodies by a standard 11 cell panel using the same technique. 
Alloantibodies of other specificities than those mentioned, as well as cold reacting 
alloantibodies are not routinely detected by the three cell panel screening method and thus 
were not considered to be included as cases of clinical alloimmunization.
medication classification
To classify the immunosuppressive therapy into corticosteroids and other immunosuppressants 
categories (table 1), the World Health Organization’s ATC (Anatomical Therapeutic Chemical) 
classification index was used (source: http://www.whocc.no/atc_ddd_index/). Medications classi-
fied under category H, sub-category H02 were included as corticosteroids; medications classified 
under category L, sub-category L04 were included as (other) immunosuppressants (table 1). 
Table 1. Immunosuppressive medication use among total study population of 468 patients
Immunosuppressive medications (98 patients)


















data Collection and definitions
Transfusion dates, results of the antibody investigations, patients’ dates of birth, gender, 
chronic obstructive pulmonary disease (COPD), infections (bacterial, viral, fungal- diagnosed 
by laboratory serological techniques including blood and tissue cultures), fever (temperature 
above 38 degree Celsius), transplants (organ and stem cell), allergies (food, dust, animal and 
chemical), autoimmune diseases (including rheumatoid arthritis), leukemia (acute lymphoblastic, 
chronic lymphocytic, acute myeloid, juvenile myelomonocytic, myelodysplastic syndrome and 
myeloma), lymphoma, chemotherapy (yes or no), surgeries (thoracic, abdominal, cranial and 
facial, upper and lower limbs and excluding coronary bypass and transluminal angiography), 
traumas (high impact traumas including cars, motorbikes and bicycles; falls) and diabetes 
(type 1 and type 2) were collected from clinical files within the defined clinical risk period 
(implicated period) of alloimmunization. Immunosuppressive medications- corticosteroids and 
other immunosuppressants used within this risk period were gathered from the hospitals’ 
electronic patient dossiers and information management systems.
data Analyses
Specific corticosteroids and other immunosuppressants types and their usage (in numbers 
and percentages) were presented.
The association between the use of immunosuppressive medications and alloimmunization 
was modeled using a logistic regression model. Odds ratios were interpreted as relative rates 
throughout the manuscript. All relative rates (RR) were corrected for the matching factors- total 
number of transfusions and study center and presented with a 95% confidence interval (CI). 
We compared patients receiving 1) any immunosuppressives, 2) exclusively corticosteroids, 
3) exclusively other immunosuppressants and 4) exclusively both of these in combination, to 
patients not exposed to any of these medications, within the implicated period.
The distribution of potential confounders in controls with and without corticosteroids 
and other immunosuppressants as well as among case patients and total study population 
(presented in the appendix) were presented in numbers and percentages, or median with 
interquartile range (IQR).
The adjusted relative rates were adjusted for – sex and age (categorical with <=25, 26-50, 
50-75 and > 75 year categories), chronic obstructive pulmonary disease (COPD, infection, 
fever, transplant, allergies, auto-immune diseases, rheumatoid arthritis (RA), leukemia, 
lymphoma, chemotherapy, surgery, trauma and diabetes type 1 and type 2 during the 
implicated period.
ReSulTS
Characteristics of the study population
Out of a total of 17,750 transfused patients, 468 patients were studied (156 case patients, 
312 control patients). 56% (261) patients were from Utrecht and 44% (207) patients were 
from the Leiden study center. The study population had a median age of 59 years, (IQR 38, 
73
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70) and comprised of 56% males. Cases had received a median of 6 units of red cells (IQR 3, 
11; range 1-66) units before antibody formation. Antibodies were detected for the first time 
after a median of 123 days (IQR 25, 333) following the first transfusion.
use of immunosuppressive therapy in the clinical risk period (implicated 
period): 
A total of 98 patients used any immunosuppressant medications. Prednisone (50%), 
prednisolone (15%) and dexamethasone (12%) were the most used corticosteroids and 
cyclosporine (34%) and mycofenolaat mofetil (22%) the most used other immunosuppressants 
(table 1).
Control patients using immunosuppressive medications (in the month before the matched 
transfusion) were more often females, 51% to 43% and younger (48 vs. 62 years) as 
compared to the patients not exposed to immunosuppressive medications. Patients exposed 
to immunosuppressive medications more often had infections (51% to 24%), fever (33% to 
23%), transplants (36% to 3%), allergies (12% to 4%), leukemia (28% to 7%), lymphoma 
(7% to 4%), chemotherapy (17% to 14%); and a lower percentage of auto-immune diseases 
(1.3% to 3%), surgeries (37% to 58%) and traumas (none to 9%) compared to patients not 
using immunosuppressive medications (table 2). The distribution of diabetes type 1 (2% to 
1%) and type 2 (8% to 9%) was similar in both patient populations.
Similar group distributions for case patients and the total study population were presented 
as well (Appendix table 1 and table 2).
immunosuppressives and risk of alloimmunization
Eight patients were left out of the adjusted multivariable analysis due to missing data on 
at least one confounder. Patients receiving immunosuppressive medications had a lower 
alloimmunization rate than those not receiving these medications. The crude relative rate 
(RR) was 0.50 (95% CI, 0.29-0.88) and the adjusted RR 0.46 (95% CI 0.23-0.89). With 
these results, we analyzed specifically patients using only corticosteroids, only other 
immunosuppressants or both (table 3).
Compared with patients not using any immunosuppressive medications, patients using 
only corticosteroids, only other immunosuppressants and patients using both all had a lower 
alloimmunization rate, an adjusted RR 0.52 (95% CI 0.23-1.16); 0.24 (95% CI 0.05-1.20) 
and 0.52 (95% CI 0.19-1.40) respectively (table 3). 
inTeRPReTATion And diSCuSSion
In our case referent study among previously non transfused, non alloimmunized patients, 
exposure to immunosuppressives was associated with a lower incidence of clinically relevant 
red cell alloantibodies against donor red blood cells. 
To appreciate these findings, several aspects need to be discussed. Strength of our 
study is the control sampling strategy. By using a risk-set sampling strategy, our control 

























































































































































































































































































































































































































































































































































































































































































































































examined the combined immune modulating effects of transfusion exposure and that of 
immunosuppressives administered in the defined implicated period. For this purpose, we 
carefully chose an implicated period. The aim of defining this clinical risk period in which the 
transfusion mediated exposure to mismatch antigens occurred, was to enable us to study 
clinical concurrent events with possible immune modulating effects. While the observed 
protective association between immunosuppressive therapy and alloimmunization may in 
part be the result of other risk factors for alloimmunization that are also associated with the 
use of immunosuppressants i.e. confounding factors, we carefully measured all other risk 
factors and adjusted for them in our analyses.
Although the possibility of unknown transfusions at a different hospital cannot be 
entirely ruled out by our strategy, all selected patients needed to have a negative antibody 
screen preceding the first transfusion and at least followed by one post transfusion antibody 
screen. This strategy is not totally excluding secondary (“boostered”) immune responses. 
We, however, do not expect this to affect our study findings. There is no reason to believe 
that patients with unknown previous transfusions and with unknown previous antibodies are 
more likely to be exposed (or unexposed) to any of the potential confounding variables. The 
same reasoning is true for the fact that we could not exclude patients with possible previous 
transfusion history in other hospitals, due to absence of such information in the transfusion 
records of the study centers. 
To our knowledge this is the first study in humans that shows the presence and extent 
of the protective effect of immune suppressive medications on alloimmunization against 
clinically relevant red cell antigens. A causal nature of the observed association with use 
of immunosuppressants is biologically plausible. Their role in suppressing the transplant 
rejection in the patients undergoing organ transplants8 has been documented. In addition, 
immunosuppressive therapy has been shown to impair humoral immune responses to 
vaccines9 and antigens10. With respect to corticosteroids, hydrocortisone has been shown to 
diminish in vitro responses to streptokinase- streptodornase and tetanus toxoid11 vaccinations 
Table 3. Relative rate of alloimmunization in patients using only corticosteroids, only other 





Crude RR*  
(95% CI)
Adjusted RR**  
(95% CI) 
None 133 237 1 (ref) 1 (ref)
Only Corticosteroids 11 35 0.52 (0.24-1.12) 0.52 (0.23-1.16)
Only Immunosuppressant 2 14 0.23 (0.05-1.08) 0.24 (0.05-1.20)
Both 10 26 0.64 (0.28-1.43) 0.52 (0.19-1.40)
* adjusted for number of matched transfusions and hospital
** adjusted for number of matched transfusions and hospital; sex, age, COPD, infection, fever, 
transplants, allergies auto-immune diseases, leukemia, lymphoma, chemotherapy, surgeries, trauma 
diabetes type 1 and diabetes type 2.
RR- Relative Rate; 95% CI- 95% Confidence Interval 
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as indication of a suppressed immune response. This diminished immune response in presence 
of corticosteroids has been attributed to transient lymphocytopenia, by the redistribution 
of circulating T-cells to other body compartments12. It has been also demonstrated that 
proliferation of T-cells can be inhibited by corticosteroids13-18. For example, glucocorticoids 
inhibit production of T-cell growth factor and block the clonal expansion necessary to amplify 
a primary response16,19,20. 
Other immunosuppressive drugs also suppress T-cell responses21. Proliferation of B and 
T lymphocytes is inhibited by immunosuppressants like mycophenolate22 and rituximab10; 
while drugs like cyclosporine and tacrolimus inhibit the activation and differentiation of 
T-cells by inhibiting calcineurin. In addition, a lower influenza vaccine antibody response 
and diminished T-cell proliferation responses have been shown in with these drugs immuno-
suppressed liver transplant patients23.
Considering the mechanisms of the studied alloimmunization against red cell antigens, 
they are both B- and T helper cell dependent. Although the short lived formation of non-
naturally occurring IgM antibodies by B-cell derived plasma cells is mainly T-cell independent, 
the subsequent memory B-cell response and the formation of more high affinity IgG is T-cell 
helper dependent. It is therefore likely that in presence of corticosteroids and the other 
immunosuppressive drugs, the T-cell mediated responses to donor red cell antigens are 
impaired. Of course, the observed immunosuppression therapy mediated risk reduction of 
alloimmunization need not be entirely caused by this therapy but a direct attributive effect 
is strongly plausible. 
Therefore when aiming for an eventual alloimmunization risk prediction on the basis of 
clinical factors, immunosuppressives might be added to such a prediction risk score. This may 
enable to distinguish high risk patients for alloimmunization that might benefit from cost 
effective extended donor blood phenotype matching strategies.
In summary, corticosteroids and other immunosuppressant medications appear to have 
a considerable protective effect on alloimmunization in patients transfused with donor red 
blood cells. While immune activating conditions are often the reason to start these drugs and 
coincide with their use, the inhibiting effect that was observed in our studies might be even 
an underestimation of the true effectiveness of these drugs to block the alloimmunization 
response. 
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In the current medical literature, etiologic and prediction research aims are frequently 
confused. Investigators tend to use principles from prediction research for their etiologic 
research questions, which results in misleading interpretation of risk-factor findings at hand. 
We used a questionnaire-based survey to quantify the proportion of ISBT 2012, Cancun 
visitors who felt confident with a causal interpretation of a stepwise logistic regression model. 
methods
We designed and distributed a short online questionnaire survey addressing questions about 
a constructed abstract entitled “Association of transfusion and clinical outcomes in a large 
cohort” among the participants of ISBT 2012, Cancun. In addition to asking questions about 
the demographics (age, sex, country of employment, and highest education level) of the 
participants, we designed seven statements representing possible interpretations of the 
findings presented in the abstract and asked the participants to mark Agree, Disagree or Do 
Not Know for each statement. 
Results
Based on the responses to these statements, we quantified the proportion of participants 
who inferred causality from stepwise multivariable models built to examine a question of 
association (or prediction).Thirty to 40% of the respondents agreed that a stepwise model was 
a valid method to adjust for confounding, and 60% of them agreed to a causal interpretation 
of a model built for prediction purposes. 
Conclusion
These findings suggest that a large proportion of ISBT visitors confuse etiology with prediction 
in the published transfusion medicine research. 
Significance
Using the results as a platform, we aim to delineate the distinction between etiologic and 
prediction research, issues of confounding accompanying these research aims and how a 




There is considerable controversy regarding the beneficial and adverse effects of blood 
transfusion1. In published observational studies, blood transfusions more often than not are 
associated with worse clinical outcomes2;3. Some authors may present these associations using 
terms that suggest causality. There is a question, however, as to whether proper methods 
have been used to investigate cause-and-effect relationships (as opposed to merely describing 
apparent associations) and to arrive at the stated conclusions. Statements on etiologic 
relations (that is, cause-and-effect relationships) and statements on predictive associations 
are frequently confused in the medical literature. This is most often illustrated by the fact that 
investigators use methods of prediction research to investigate etiologic research questions4;5.
The aim of prediction research is to measure the likelihood of occurrence of a disease 
based on risk factors associated with the disease; the aim of etiologic research is to examine 
the causal relationship between a risk factor and the occurrence of a particular disease or 
outcome. 
In transfusion-related studies, this misuse of prediction research methods intended for 
etiologic (causal) questions leads to misinterpretation of the “independent risk factors” 
identified in multivariable regression models as causal factors. To investigate the extent of 
this misinterpretation (or the extent to which an inference of causality was drawn from 
multivariable models), we conducted a survey of transfusion-medicine specialists, clinicians 
and researchers who attended the International Society for Blood Transfusion conference in 
Cancun in July 2012. In this report, we use the results of the survey as a basis for discussion of 
the methodological differences between etiologic research and prediction research, including 
the role of confounding and how multivariable models should be used differently to study 
questions from prediction research versus etiologic research.
QueSTionnAiRe bASed SuRVey meTHodS
We designed a short online questionnaire survey addressing questions about a constructed 
abstract entitled “Association of transfusion and clinical outcomes in a large cohort” 
(Figure 1). This abstract was based on an actual abstract presented in one of the previously-
held major hematology conferences. The questionnaire was sent out to the International 
Society of Blood Transfusion (ISBT) members who attended the ISBT conference at Cancun, 
Mexico in July 2012. In addition to asking questions about the demographics (age, sex, 
country of employment, and highest education level) of the participants, we designed seven 
statements representing possible interpretations of the findings presented in the abstract 
(or of the inferences that could be made from the methods used in the hypothetical study), 
and we asked the participants to mark Agree, Disagree or Do Not Know for each statement. 
Based on the responses to these statements, we quantified the proportion of participants 
who inferred causality from stepwise multivariable models built to examine a question of 
association (or prediction). An Apple iPad 2 was awarded to a lucky winner out of all the 
participants who completed the questionnaire.
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ReSulTS FRom THe QueSTionnAiRe
Of 435 participants, 398 provided complete demographic information. The mean (Standard 
Deviation) age of participants was 52.6 (11) years and did not differ between male and female 
attendees. Nearly 40% of participants had a master’s degree/ professional degree or field of 
specialization; 35% of participants had a doctorate (Appendix- Figure A). Almost a quarter 
of all responders were employed in Northern or Western Europe, 18% in North America and 
12% in South East Asia or the Indian subcontinent (Appendix- Figure B). Not all participants 
responded to all 7 statements of the questionnaire pertaining to the interpretation of the 
results of the abstract, with fewer and fewer participants committing themselves to each 
successive statement. In this way, 351 participants answered the first statement, while 298 
participants responded to all 7 statements. 
Figure 2 presents the seven abstract-related statements and the frequency of responses 
to these statements. Statements 2, 4, 5 and 6 deal with how methods of prediction research 
are misused in studies aiming to answer cause-and-effect research questions. Between 35 
and 50% of responders agreed (wrongly) with these statements (Figure 2). Statements 1 
and 7 straightforwardly refer to a causal interpretation of the research aim of the abstract, 
despite the fact that prediction research methods were used in the study. Between 45-60% 
responders agreed (wrongly) with these statements. 
The answers to statement 3 were difficult to interpret since the phrasing “cannot” might 
have been interpreted as “were not” by survey participants.
The correct combination of answers was disagree, disagree, agree, disagree, disagree, 
disagree and disagree. This combination was “achieved” by 17 participants. 
ConCluSionS bASed on SuRVey ReSulTS
Our findings show that almost 60% of our sample of attendees at the 2012 ISBT conference 
at Cancun inferred causality from models built to serve mere prediction purposes (Figure 2, 
statement 7). 
diSCuSSion
How do questions addressing etiology differ from those addressing 
prediction?
“Predicting outcomes is not synonymous with their cause. 
Every causal factor is a predictor—albeit sometimes a weak 
one—but not every predictor is a cause”6.
An Etiologic question by definition aims to establish causality. In other words, the aim is to 
asses if an outcome can be attributed to a particular risk factor, following adjustment for 
other potentially causal factors or confounders. The focus usually is on a single potentially 
causal factor at a time and confounding is the cardinal issue that must be dealt with in 
etiologic research. This is discussed in detail in the following sections. 
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A Prediction question by definition is merely descriptive. It aims to estimate the probability 
of occurrence of an outcome given a combination of a patient’s clinical or non-clinical 
attributes. Predictive research does not asses the cause of the outcome; predictive factors may 
or may not be causally related to the outcome but confounding is a non-issue in predictive 
research6. The development of the widely used Sokal Score for the prognosis of chronic 
myeloid leukemia (CML) is a good example of predictive research. In this instrument7, age, 
cytogenetic evaluation, circulating blast cells and spleen size are used as predictive factors 
to estimate the probability of a good versus bad prognosis for CML patients. The factors 
included in the instrument need not be causal (for example, spleen size may be predictive of 
the outcome in CML, but is surely not the cause of CML), nor do they need to be associated 
with mortality from CML; all they need to do is predict the course or prognosis of CML.
The importance of confounding (especially in etiologic research as opposed to prediction 
research) makes it essential to clearly define the study aim and the risk factors in question; 
to understand which multivariable methods have to be used for etiologic (as opposed to 
predictive) questions; and also to understand what multivariable modeling can (and cannot) 
do. The bottom line is that a different model needs to be built if the question addressed by 
the study is etiologic versus predictive.
Which myths on multivariable modeling lead to its misuse? 
What does a multivariable model do? A multivariable model attempts to describe the data 
using multiple independent variables. Depending on the method to select these variables, 
a multivariable model attempts to create the best model fit. Given the information (from 
independent variables) at hand, a multivariable model attempts to determine a formula (or a 
regression line) which best describes the data.
myths of multivariable models in etiologic research
A common assumption is that a multivariable model, resulting from entering multiple variables 
available from the dataset into a logistic (or linear) model, will ensure that all confounding 
in the study has been taken care of. This is an incorrect assumption. Three key issues need 
to be addressed regarding confounders and a multivariable regression model- a) selection of 
confounders, b) possible introduction of selection bias by adjusting for a non- confounder 
and c) treatment of intermediate variables as true confounders. 
a) Confounder selection with stepwise regression
“The data analyst knows more than the computer and failure 
to use that knowledge produces inadequate data analysis”14.
Automated procedures like stepwise regression are used to select variables (covariates- a 
covariate is a variable in a multivariable model) for a multivariable model, based on the 
p values. A multivariable stepwise regression uses every strong (statistically significant) 
association (between each of the variables and the outcome) to describe the data. Although 
statistically strong predictive associations between covariates and the outcome need not be 
causal, they are mistaken as causal when the results are interpreted. 
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In essence, a researcher lets the software decide on the covariates based on the entry 
criteria of the stepwise regression, which is a low p value or some equivalent of the p value. 
However, by this approach, important confounders can be removed from the model whereas 
“background-noise” variables may be retained15. This problem has been recognized and 
eloquently summarized before16. Subject matter knowledge coupled with good statistical 
oversight offer better guidance and they are essential to ensure that only relevant covariates 
are selected and entered into a model8.
b) Introduction of selection bias by adjusting for a non- confounder 
Consider an example below where one intends to examine the association between presence 
of HLA antibodies in patients and mortality. We will proceed with an example using directed 
acyclic graphs9 (DAGs, Appendix: Rules for drawing a Directed Acyclic Graph) as a visual 
representation aid. Few things that we know a priori are (see figure 3 below):
1. Patient’s sex is associated with the presence of HLA antibodies. Women tend to have a 
higher rate of HLA antibodies due to pregnancy.
2. Patient’s age is associated with mortality. Older patients are at a higher risk of dying.
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Next, one decides to adjust for number of red cell transfusions as a confounder. A couple of 
things we know a priori are (see figure 4 below): 
1. Number of transfusions is associated with patient sex. Male patients on average receive more 
transfusions than female patients because of a higher rate of traumas and cardio-vascular 
surgeries. 
2. Number of transfusions is associated with patient age. Older patients tend to receive more 
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Next, one decides to adjust for number of red cell transfusions as a confounder. A couple of 
things we know a priori are (see figure 4 below):
1. Number of transfusions is associated with patient sex. Male patients on average receive 
more transfusions than female patients because of a higher rate of traumas and cardio-
vascular surgeries.
2. Number of transfusions is associated with patient age. Older patients tend to receive 




Now, controlling for number of transfusions would create a (false) association between 
patient sex and age (see figure 5 below). This implies that if patients with higher number of 
transfusions are female, they must be old; while younger patients must be male. Otherwise 
they would not have received these many transfusions. Thus, the probability of dying is 
higher in women, due to the average older age in this group, which is a result of the false 
association created by controlling for the number of transfusions. HLA antibodies occur 
predominantly in female patients and therefore also become associated, through higher age 
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sex and age (see figure 5 below). This implies that if patients with higher number of transfusions 
are female, they must be old; while younger patients must be male. Otherwise they would not 
have received these many transfusions. Thus, the probability of dying is higher in women, due 
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This is a classic example of “M- Bias”9 (referring to the shape of the DAG) in epidemiological 
research methods which induces a spurious statistical association between two variables9;10. 
c) Adjusting for an intermediate variable in the causal pathway 
As an illustration, one can think of a study aiming to examine a causal relationship between a 
patient’s hemoglobin level and mortality. It is often presumed that entering the number of red-
blood-cell (RBC) transfusions received by the patient into the model will control for confounding 
by transfusion. This is an unfounded assumption because such a variable is not a true 
confounder but an intermediate variable; consequently, entering it into a multivariable model will 
not ensure that it has been adjusted for. This is illustrated in more detail in the next section. 
 Sex 
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Fig. 5 
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Figure 5
This is a classic example of “M- Bias”9 (referring to the shape of the DAG) in 
epidemiological research methods which induces a spurious statistical association between 
two variables9;10.
c) Adjusting for an intermediate variable in the causal pathway
As an illustration, one can think of a study aiming to examine a causal relationship between 
a patient’s hemoglobin level and mortality. It is often presumed that entering the number 
of red-blood-cell (RBC) transfusions received by the patient into the model will control for 
confounding by transfusion. This is an unfounded assumption because such a variable is not 
a true confounder but an intermediate variable; consequently, entering it into a multivariable 
model will not ensure that it has been adjusted for. This is illustrated in more detail in the 
next section.
The myths of multivariable models discussed above do not pertain to prediction models, 
but etiologic research models only.
ConFounding 
A variable is a confounder if it is a common cause of the single etiologic determinant of 
interest (the “exposure”) and the outcome under study. For example, in a study (Figure 6 
below) to determine the association between number of RBC transfusions and mortality, the 
severity of a patient’s illness would be a confounder. 
In an etiologic study to determine if the number of transfusions causes patient 
mortality, the severity of a patient’s illness would be a confounder which distorts any true 
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causal relationship between the number of transfusions and the mortality. Directed Acyclic 
Graphs (DAGs)9 are an elegant way to visualize and thus facilitate identification of potential 
confounders. It is important to adequately plan the measurement of potential confounders 
in the design phase of the study. In this way, they can be documented during the study and 
then controlled (adjusted) for in a multivariable model. (see below)
Next, a variable is not a confounder if it merely lies in the causal pathway between 
the exposure of interest and the outcome. The exposure of interest should not determine 
the presence or absence of this “confounder”. For example in figure 7, we show the 
association between receiving plasma or platelet transfusions and mortality, among patients 
who experienced massive blood loss after the transfusion event. Decreased blood loss after 
platelets/ plasma transfusion is not a true confounder; instead, the decreased blood loss 
after plasma/ platelet transfusions is a causal intermediate variable in the pathway between 
plasma/ platelet transfusions and mortality (Figure 7 below).
The myths of multivariable models discussed above do not pertain to prediction models, but 
etiologic research models only. 
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In an etiologic study to determine if the number of transfusions causes patient mortality, the 
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Confounding by Indication 
Patients receive blood transfusions based on their need for such intervention, in other words, 
based on their indication for transfusion. Transfusion medicine research with causal claims is 
rife with this type of confounding. This is particularly the case if researchers attempt to find 
causality between transfusions and adverse outcomes. 
Sicker patients tend to get more transfusions, and also tend to have worse outcomes. This 
causes distorted associations between amount of transfusions and worse outcomes, and 
consequently the danger that these associations are over-interpreted. This type of confounding 
usually goes unmeasured11, but if measured well, it could be dealt with12:  
a) at the stage of study design by 1) clearly defining the outcomes of interest and the 
exposure; 2) careful considering other determinants which may be related to the risk 
factors for the outcomes (for example, by careful consideration of the clinical setting in 
Plasma/ platelet 
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Patients receive blood transfusions based on their need for such intervention, in other words, 
based on their indication for transfusion. Transfusion medicine research with causal claims is 
rife with this type of confounding. This is particularly the case if researchers attempt to find 
causality between transfusions and adverse outcomes.
Sicker patients tend to get more transfusions, and also tend to have worse outcomes. 
This causes distorted associations between amount of transfusions and worse outcomes, 
and consequently the danger that these associations are over-interpreted. This type of 
confounding usually goes unmeasured11, but if measured well, it could be dealt with12: 
a. at the stage of study design by 1) clearly defining the outcomes of interest and the 
exposure; 2) careful considering other determinants which may be related to the risk 
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factors for the outcomes (for example, by careful consideration of the clinical setting in 
which blood is given) and 3) only studying patients with similar risk factors and measuring 
such risk factors well to allow for correction at the analysis stage;
b. at the stage of statistical analysis by using stratification of patients in risk groups. This 
approach helps to characterize the interdependence between the potential confounding 
factors and transfusion (which is the single exposure of interest). 
In summary, identification of all possible and likely confounders (and illustrating them for 
example, by using causal diagrams/ directed acyclic graphs) and adequate measurement 
and correction for the identified confounders are all necessary in etiologic/causal research. 
Computerized stepwise multivariable modeling on the basis of p values is the wrong method 
for doing this, because it may very well omit true confounders. Why this is so will be further 
illustrated in the next three sections.
How regression modeling deals with (or adjusts for) confounding in 
etiologic research?
step 1: unadjusted regression model
Regression is a technique used to assess the association between two variables. For example, 
looking at the association between number of RBC transfusions and patient mortality (Fig. 8) 
the linear regression equation would be y = β0 + β1 x, where
y = outcome: mortality
x = determinant: number of transfusions
β0 = intercept: estimated value of y when x = 0, (Base value)
β1 = coefficient (slope of regression line): change in mortality risk per unit increase in the 
number of transfusions
The regression equation is Mortality = Base value + (co-efficient*number of transfusions) The regression equation is Mortality = Base value + (co-efficient*number of transfusions)      
                         
                                                       






Figure 8 above represents that for each additional RBC transfusion, the risk of patient mortality 
increases by a factor of β1.  
Confounder- As described previously (Figure 8 above); severity of illness will be a confounder if 
it is a common cause of the outcome of interest (mortality) as well as the exposure (number of 
transfusions). We present it graphically in two steps. 
 
Step 2: Confounder associated with the outcome 
Severity of illness is associated with patient mortality. More severely ill patients will have a 





                                                                                      








y = β0 + β1 x 
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Fig. 9: Severity of illness as the cause of mortality 
Figure 8 above represents that for each a ditional RBC transfusion, the risk of patient 
mortality increases by a factor of β1.
Figure 8. Unadjusted model
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Confounder
As described previously (Figure 8 above); severity of illness will be a confounder if it is a 
common cause of the outcome of interest (mortality) as well as the exposure (number of 
transfusions). We present it graphically in two steps.
step 2: confounder associated with the outcome
Severity of illness is associated with patient mortality. More severely ill patients will have a 
higher risk of dying (see below, figure 9).
The regression equation is Mortality = Base value + (co-efficient*number of transfusions)      
                         
                                                       






Figure 8 above represents that for each additional RBC transfusion, the risk of patient mortality 
increases by a factor of β1.  
Confounder- As described previously (Figure 8 above); severity of illness will be a confounder if 
it is a common cause of the outcome of interest (mortality) as well as the exposure (number of 
transfusions). We present it graphically in two steps. 
 
Step 2: Confounder associated with the outcome 
Severity of illness is associated with patient mortality. More severely ill patients will have a 
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Fig. 9: Severity of illness as the cause of mortality 
Figure 9. Severity of illness as the cause of mortality
Step 3: confounder associated with the exposure 
Severity of illness is also associated with the number of transfusions. More severe patients will 
receive a higher number of transfusions (see below, figure 10).
Step 4: adjustment for confounding 
We can visualize the confounding by stratifying the data by severity of illness or by correcting 
for the confounder as in Fig 11 below. By doing this, we indeed observe that the patient 
mortality is not dependent on RBC transfusions (it is a horizontal line) if we examine this 
association separately within the group of severely-ill and within the group of not-severely-ill 
patients. Yet, the unadjusted (dotted) regression line in Step 1, Fig 8) shows an association 
 
Step 3: Confounder associated with the exposure  
Severity of illness is also associated with the number of transfusions. More severe patients will 
receive a higher number of transfusions (see below, figure 10). 
  
                                         






Step 4: Adjustment for confounding  
We can visualize the confounding by stratifying the data by severity of illness or by correcting for 
the confounder as in Fig 11 below. By doing this, we indeed observe that the patient mortality is 
not dependent on RBC transfusions (it is a horizontal line) if we examine this association 
separately within the group of severely-ill and within the group of not-severely-ill patients. Yet, 
the unadjusted (dotted) regression line in Step 1, Fig 8) shows an association between 
increasing number of transfusions and risk of dying, because the model is merely trying to best 
fit a line through the data to account for the increased mortality in the severely-ill patients.  
However, the resulting fitted line does not depict a true relationship between the number of RBC 
transfusions and mortality; instead, it demonstrates illness severity as a cause for both the 
number of RBC transfusions received and mortality (shown in Step 2 and Step 3). By stratifying 
the data into potential confounder categories, it becomes apparent why the unadjusted line 
shows the association of mortality with a patient’s increasing number of transfusions (Fig 11). 
 
 
Number of transfusions 
Not Severe 
Severe 
Fig. 10: Severity of illness as the cause of number of transfusions 
Figure 10. Severity of illness as the cause of number of transfusions
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between increasing number of transfusions and risk of dying, because the model is merely 
trying to best fit a line through the data to account for the increased mortality in the severely-
ill patients. However, the resulting fitted line does not depict a true relationship between the 
number of RBC transfusions and mortality; instead, it demonstrates illness severity as a cause 
for both the number of RBC transfusions received and mortality (shown in Step 2 and Step 3). 
By stratifying the data into potential confounder categories, it becomes apparent why the 










Building a multivariable model in predictive research 
Predictor selection: Conduct univariate analysis for each (previously identified or newly 
suspected) predictor. This provides an idea on potentially important predictors based on their 
statistical significance, and it also serves as a guide to cluster/combine determinants/predictors. 
Predictor inclusion: Based on the p values from the univariate analysis and pre-existing 
knowledge, costs, invasiveness of the tests or procedures pertaining to each predictor and other 
practicalities, run a multivariable analysis including or excluding predictors based on a pre-
determined inclusion/ exclusion criterion based usually on p values. The next step is calibration 
and discrimination of a prediction model, which is beyond the aim and scope of this article. 
 
Building a multivariable model in etiologic research 
Confounder inclusion: One should include confounding variables based on a plausible biological 
hypothesis or an a priori reasoning, irrespective of their statistical significance, that is, 
regardless of the p values.   
Confounder selection: One should first tabulate risk factors according to presence or absence of 
the exposure of interest to obtain a summary of risk-factor distribution in the study population. If 
a risk factor differs between those with and without the causal factor of interest, it is a 
confounder of the association in the study.  
When interpreting the results, one should discuss incomplete adjustment from residual 
confounding. This may occur if important confounders are not known or are not measured 






building a multivariable model in predictive research
Predictor selection
Conduct univari te analysis for each (previously identified or newly suspected) predictor. Thi  
provides an idea on potentially important predictors based on their statistical significance, 
and it also serves as a guide to cluster/combine determinants/predictors.
Predictor inclusion
Based on the p values fro  the univariate analysis and pre-existing knowledge, costs, 
invasiveness of the tests or procedures pertaining to each predictor and other practicalities, 
run a multivariable analysis including or excluding predictors based on a pre-determined 
inclusion/ exclusion criterion based usually on p values. The next step is calibration and 
discrimination of a prediction model, which is beyond the aim and scope of this article.
building a multivariable model in ti logic r search
confounder inclusion
One should include confounding variables based on a plausible biological hypothesis or an a 
priori reasoning, irrespective of their statistical significance, that is, regardless of the p values. 
confounder selection
One should first tabulate risk factors according to presence or absence of the exposure of 
interest to obtain a summary of risk-factor distribution in the study population. If a risk factor 
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differs between those with and without the causal factor of interest, it is a confounder of the 
association in the study. 
When interpreting the results, one should discuss incomplete adjustment from residual 
confounding. This may occur if important confounders are not known or are not measured 
during the study; if an improper surrogate variable (for a confounder under investigation) has 
been used; or if the categories of a confounding variable have not been defined correctly, 
especially when recoding a continuous confounder in to a categories.
ConCluSion
Our findings from a blood transfusion survey conducted among the participants of ISBT 
2012, Cancun suggest that a large proportion of ISBT visitors confused etiology with 
prediction in the published transfusion medicine research. We feel that in the conduct of 
clinical transfusion medicine research, as well as at a major international transfusion and 
hematology conference, there is insufficient emphasis on research methodologies, strategies 
to handle confounding, and the fundamentals of data analysis. International and regional 
seminars, congresses, focus groups and working party meetings can all be opportunities 
to organize special education sessions on these matters. Furthermore, additional modules 
or sessions on research methodology must be added to the formal training of transfusion 
medicine researchers and specialists to better equip these professionals to bridge the gap 
between the evidence-base for transfusion medicine and clinical practice.
Focus Points
1. Association arising from a prediction research methodology does not imply causation.
2. Confounding is the cardinal issue that must be dealt with in etiologic research.
3. Causality is often implied from the output of a multivariable model. Careful review of 
study aims and research methods is required to interpret causation from association.
4. Multivariable model by itself does not take care of confounding. 
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The aim of the research presented in this thesis was to quantify the problem of alloimmunization 
among a general transfusions receiving, previously non-alloimmunized, and non-transfused 
population; and to examine potential transfusion-related and clinical risk factors associated 
with alloimmunization. 
Every red blood cell transfusion (obligatory) introduces a myriad of foreign antigens, yet 
the majority of transfusion recipients do not alloimmunize against non-self red blood cells1. 
Alloimmunization is a multi-factorial immune event involving a genetic and a non-genetic 
component in which several risk factors need to be simultaneously present. In essence, every 
transfusion recipient has a unique or specific clinical profile, has been exposed to certain 
environmental immune modulating conditions and possesses a unique set of genes governing 
the immune response.
The primary aim of the R-FACT study at the time of its inception was to be able to classify 
transfusions receiving patients as a high risk or a low risk group for alloimmunization. If 
successful, a risk specific preventive matching strategy could be applied to especially such 
high risk patients thus avoiding alloimmunization in the first place. To put it in perspective, low 
at risk patients against alloimmunization would not require preventive matching strategies 
thus avoiding the logistical burden of obtaining timely and proper matched blood for their 
phenotype, as well as saving costs. 
To study risk factors associated with a first time alloimmunization event in a general 
transfused patient population in an observational setting, it is essential to have a robust study 
design; and a considerable amount of time and effort is required. To appreciate the findings 
presented in this thesis, it is necessary to first discuss the nuances of the study designs chosen 
(chapter 2).
Our source population was based on an incident new user cohort. All the case patients were 
incident case patients with no prior history of transfusions and alloimmunization, to the best 
of our knowledge. Such a new user cohort avoids selection of prevalent transfusion recipients 
as well as existing (prevalent) case patients in the source population. Our data collection 
approach allowed a prospective follow up of previously non-transfused and non-immunized 
patients during subsequent transfusions up to the appearance of a first alloantibody. We thus 
feel that this cohort ideally represents the general transfused population and is appropriate 
to study the incidence of first time alloimmunization.
A matched case- referent study was designed where cases were defined as first time ever 
alloantibody formers against clinically relevant red cell antigens with no previous transfusion 
history. Next, selection of control patients is important, as it should be a representative 
sample of the source cohort. Potential controls were all consecutive first time transfused 
patients at our two study centers with no previous history of alloimmunization. For every case 
patient, we selected two control patients from the new user cohort, who had at least the 
same number or more transfusions than the case patient. This ensured that all the patients in 
the transfusion cohort with the same or higher number of transfusions had an equal chance 
of being picked as control patients. In essence, any member of the cohort (including case 
patients) who had been at a similar transfusion risk (of alloimmunization) at some point in 
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their transfusion history could be selected as a control patient. In short, we used a risk-set 
sampling strategy (Book: Modern Epidemiology- 3rd edition by Kenneth J. Rothman; chapter 
8- Case- Control studies- Variants of case- control design), and then matched control patients 
to the case patients on the number of transfusions received up until antibody formation, and 
the hospital. Straightforward comparison of alloimmunizers and non- alloimmunizers from 
a hospital database leaves room for selection bias where control patients do not represent 
the source population well in terms of transfusion exposure and well as other risk factors2.
Further, since the exposure itself is the foremost risk factor for an adverse event, we 
matched the case patients and control patients on the number of transfusions to study 
the clinical risk factors in a matched case- referent study design. In the studies where we 
used a follow up new user cohort design (chapters 3 and 5), we stratified patients on the 
number of red cell units and presented their alloimmunization risk. This was especially 
relevant since a transfusion and every subsequent transfusion might present a different risk 
of alloimmunization. Thus, by using a Kaplan- Meier survival analysis and using the number 
of cumulative transfusions as the time axis, we were able to quantify alloimmunization risk 
with a relative simple but elegant approach.
To study immune modulating clinical risk factors and their effects of alloimmunization, 
another obstacle needs to be addressed. It is important to identify and define a clinical risk 
period (or a so called implicated period) in which the antigen mismatch (exposure) coincided 
with pre-defined risk factors leading to modulation of the immune. 
A “clinical risk period for alloimmunization” or an “implicated period” was thus defined 
for cases as the period in which transfusion most likely caused the observed primary 
alloimmunization. This implicated period was the time (in days) between the last transfusion 
(Nth) before the first positive alloantibody screen and 30 days earlier3. A similar implicated 
period was selected for the controls, which was a period of 30 days preceding the Nth 
transfusion. Potential transfusion related risk factors and clinical risk factors present in this 
implicated period were studied.
Confounding is a major concern in etiological studies. Combining a priori knowledge 
together with subject matter knowledge, we defined and measured the confounders and 
then adjusted for them in our analyses.
TRAnSFuSion eXPoSuRe
What was known?
Red blood cell transfusions likely determine exposure to alloantigens and the risk for subsequent 
antibody formation. Existing evidence quantifying the problem of alloimmunization has 
been overwhelmingly documented in either specific patient groups4,5 or in patients with a 
pre-study transfusion history6,7. Evidence in the literature also pointed out to an increased 
risk of alloantibody formation with higher number of transfusions, although some of these 
studies again included patients with pre-existing antibodies8 or included patients receiving 
extensively matched transfusions due to their predisposing conditions9,10. Alloimmunization 
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risk for first time ever formed antibodies as a function of the number of transfusions was not 
reported before.
Besides the number of transfusions as a risk factor against alloimmunization, the dose or 
intensity of these RBC transfusions could potentially also have an impact on alloimmunization 
risk. The impact of intensive (or massive) transfusions on adverse outcomes has been reported 
with massively transfused patients at a higher risk of developing systemic inflammatory 
response syndrome (SIRS)11,12 and mortality12 as adverse patient outcomes11-13, yet their 
impact on alloimmunization was surprisingly unknown.
What did we add?
In chapter 3, we designed a new incident user cohort14 study in a general transfused patient 
population with no pre-study transfusion and alloimmunization history documenting the 
cumulative incidence of a first time ever red cell alloimmunization. Stratified on the number 
of transfusions received, we found that the risk of alloimmunization increases up to 7% at 
the 40th transfused unit, and that the risk was comparable between men and women.
In chapter 5, using a new user cohort study design, we examined the association between 
transfusion intensity and the risk of clinically relevant RBC alloantibody formation in a 
previously non-transfused, non-alloimmunized cohort. Special emphasis was put on different 
amounts of intensive transfusions, since there is no consensus on a uniform definition in the 
literature15,16. However, we did not find a difference between the intensively transfused (with 
intensive transfusions studied separately as ≥5, ≥10 and ≥20 units transfused in 48 hours) 
and non-intensively transfused patients, and their risk of alloimmunization.
interpretation
Patients receive mismatched blood during their transfusion histories, but most of these do 
not for alloantibodies against the mismatched blood. Patients who do not alloimmunize 
after few initial transfusions tend not to make antibodies against subsequent transfusions. 
We observed this in our study estimating the incidence of alloimmunization in a general 
transfused population and found no more than 7% alloimmunizers even with very high 
exposure of transfusions. The “responder” hypothesis1,17 in this respect signifies that only 
a small part of the population is able to mount a red blood cell alloimmunization. Some 
additional patients however do form alloantibodies even up until 40th transfusion and 
within the studied patient cohort we could not yet observe a leveling of the frequency of 
alloimmunization as a function of exposure. The latter could indicate that there really exists 
a limited population of responders, who will eventually respond to an alloantigen. What we 
do can conclude is that within clinically relevant transfused amounts there is a very large 
population of patients that form no antibodies. Off course this large population includes 
patients that are heterozygotic for many antigens and that therefore despite receiving large 
number of transfusion may not encounter a rare antigen (for example- K, 9% in Caucasians, 
2% in blacks and 25% in Arabs) mismatch and that thus are not triggered to form antibodies 
even in a large number of transfusions. 
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Secondly, within the responders we have to acknowledge that alloimmunization is a 
multi-factorial determined event, clinical and other non-genetic determined risk factors for 
alloimmunization that can only be detected in patients that detect non-self antigens. Finally, 
it cannot be said if responders are perhaps genetically programmed to respond or that non 
responders are genetically protected.
What next?
With the evidence from our study on the incidence of alloimmunization and the number 
of red cell transfusions, a hypothesis is generated that many patients with many exposures 
(more than 40 transfusions) may be required to assess if there is a fixed number of responders 
in the general transfused population. Using similar principles of incidence new user cohort 
but with a larger study population as well as longer follow up period in this respect would 
be useful in following patients who received greater than 40 red cell transfusions. Although 
there are very few patients receiving such large number of transfusions, and hence may not 
seem to be of clinical relevance, nonetheless this would enable to also identify a certain 
group of never-responding transfusion recipients. Such patients might harbor a potential 
“protective” genotype or phenotype that prevents alloimmunization.
SToRAge Time oF TRAnSFuSed Red CellS
What was known?
Red blood cells undergo various biochemical and biomechanical changes during storage. 
Besides, there are residual leucocytes and platelets present in stored blood, and the 
accumulation of released lipids, cytokines and histamine have been reported in suspension 
solution18-22. The clinical importance of these changes in stored red cells is much debated23-26. 
Currently there is no evidence in humans if and how the present transfusion storage times 
modulate the risk of alloimmunization. 
What did we add?
Using the case referent study design, we next studied if the storage time of transfused red 
blood cells was associated with the risk of alloimmunization, (chapter 4). Given our study 
design and population, we found that the storage time of red blood cells is not associated 
with post-transfusion risk of alloimmunization within the clinically relevant storage time 
ranges of 7-28 days. 
interpretation
An interpretation and explanation of the fact that we did not observe an association 
between older (or younger stored red cells) in our study could in theory be attributed to two 
“heightened” periods of danger that change differently with storage time – 1) increasing 
immunogenicity by leukocyte activity in fresher units and decreasing with storage, and 
2)  immunogenicity by accumulation of cytokines, lipids, histamines and micro-vesicles that 
increases with storage. The similar alloimmunization risk that we observed for ‘old and 
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young’ blood might thus be due to (e.g. the two mentioned) risk factors which sum remains 
constant throughout the investigated storage period. 
What next?
Of conceptual value would be to study the effect of less than 7 days (very young) stored blood 
and blood stored for more than 28 days (very old) on the risk of alloantibody formation. The 
debate in literature is how long blood can be stored before it induces detrimental clinical 
effects. Studying such questions and comparing various contrasts from 7 days younger to 
28 days and older would give an indication on “when does the stored blood start displaying 
immunologic activity”; the study on the biological mechanisms could follow.
PATienT RelATed RiSk FACToRS
Sex
What was known?
The alloimmunization risk to red blood cell antigens is suggested to be higher among women as 
studies have pointed out female sex to be an independent risk factor for alloimmunization2,5,27,28. 
It is important to note that this higher risk in the above mentioned studies is found in the 
presence of various selection biases- a) higher number of transfusions29, b) more women 
with diseases with an intrinsic higher allo-response like auto immune hemolytic anemia30 or 
sickle cell disease and c) longevity of women with such diseases (sickle cell diseases31) and 
d) previous pregnancies as well known trigger/ primer for alloimmunization. The review31 
suggested that women not be considered as a high risk group for alloimmunization.
What we added?
In our new incident user cohort (chapter 2), we showed that the alloimmunization rate 
was comparable for men and women over the age of 45 years. Additionally, young women 
in potentially reproductive age who additionally received K- matched transfusions (as per 
transfusion policy in the Netherlands) showed an immunization rate comparable to men and 
older women who received equal amounts of only ABO-D matched transfusions.
Furthermore, in our case- referent study design, we examined the association of sex with 
the risk of alloimmunization and found again (results not shown in this thesis) to be similar 
between men and women.
interpretation
It has to be noted that information on previous pregnancies in women was not available in 
our studies, due to the limited or no availability of this information in the hospital patient 
management systems. Yet, adjusting for other potential confounders including number of 





Antigen mismatched transfusions are the most obvious requirement for an allo-response. 
However, inflammation state of a transfusion recipient as dictated by his or her clinical 
morbidity are also likely to influence immune responses17. In this respect not only existing 
morbidities but also the use of concomitant medication could play a role in adaptive immune 
response towards alloantigens2. Diabetes, solid malignancies and progenitor cell transplants 
were associated with a higher risk of clinical alloimmunization2; and lympho-proliferative 
disorders and atherosclerosis with a lower risk of alloimmunization2. 
To study potential patient related risk factors against alloimmunization, we identified 
immunosuppressive therapy as one of the most interesting starting points. We found this 
especially interesting because many patients – such as trauma patients, intensive care patients, 
patients with active autoimmune disorders, patients with cancer and patients undergoing 
organ transplants- receive both red cell transfusions as well as immune suppressing drugs-. 
Use of corticosteroids and other immunosuppressive therapy among a general transfused 
population and its implicated inhibiting effect on the risk of alloimmunization against 
clinically relevant red cell antigens, however, has not been studied. 
What did we add?
Using the case-referent study design of the ongoing R-FACT study with matched cases and 
controls (chapter 6), we found that exposure to immunosuppressives was associated with 
a lower incidence of clinically relevant red cell alloantibodies against donor red blood cells. 
interpretation 
A causal nature of the observed association with use of immunosuppressants is biologically 
plausible. Immunosuppressive drugs, including corticosteroids have been shown to impair 
humoral responses to vaccines32,33; T- cells have been shown to lose their proliferative ability 
under corticosteroids and other immunosuppressive drugs impair T-cell responses34-39. With 
the notion that antibody responses against red cell antigens are T- cell help dependent, it is 
therefore likely that corticosteroids and the other immunosuppressive drugs might in part 
inhibit red cell alloimmunization via T-cell modulation. Of course, while only associations 
were tested, and while the observed immunosuppression therapy mediated risk reduction 
of alloimmunization need not be the entirely caused by this therapy, but a direct attributive 
effect is strongly plausible.
What next?
For many reasons, immunosuppressives cannot be standard administered to transfusion 
recipients in order to lower their alloimmunization risk. But importantly, this knowledge 
should be applied to a clinical risk score (in combination with other clinical risk factors) to 




Other clinical factors to consider would be presence or absence of chronic diseases 
like diabetes, auto-immune diseases, allergies; acute stresses like surgeries, infection, stem 
cell transplants and in addition- leukemia, carcinoma; thus a list of factors representing 
a generally activated immune system. Apart from that, certain medication types (anti-
neoplastic medications, systemic hormones, antibiotics, chemotherapy) are likely to influence 
(or alter) the immune system’s responses towards foreign antigens and thus the process of 
alloimmunization. Assessing them each in detail would shed light on a possible high risk 
group of patients who are susceptible to alloimmunize; which are the aims of the ongoing 
R-FACT study.
AddiTionAl RiSk FACToRS FoR FuTuRe ConSideRATion
environment
What was known?
The “antigenic” environment or the nurture where one was born or raised with might 
also be associated with an altered “education” of the immune system and with it, another 
set point of the response to non-self antigens. Environmental factors such as exposure to 
helminthic, fungal and parasitic agents do play a role in modulating the general set point of 
the immune response at young age40. The same is true for living in unsanitary conditions and 
for unhygienic occupations throughout life41.
The hygiene “hypothesis” in this respect is supported by epidemiologic studies and 
proposes that insufficient stimulation of T helper 1 cells (by bacteria and viruses) leads to an 
over active T helper 2 cell response skewing towards antibody mediated immune response42. 
It moreover, suggests that a lack of exposure to antigens, micro-organisms and parasites 
during early life could leave a person susceptible to immune system impairment in later 
life43. Certain autoimmune and allergic diseases have been linked to such skewed hygiene 
conditions43,44. 
What next?
Information on the antigenic environments during formative years- country, rural or urban 
places of residence, regular contact with farm animals and pets, stay at day care centers 
during childhood and socio-economic status information; could add to the knowledge 
in predicting a patient’s risk against alloimmunization. This information on transfusion 
recipient’s environment related immune modulation conditions is currently being collected via 
questionnaires in the R-FACT study. Such information on immune modulating environmental 
condition should be added as well to a prediction risk score discerning high and low at 
risk for alloimmunization patients. In addition, this information would also stimulate further 
research on the mechanism of immunization in general- on how T helper 1 and T helper 2 




A patient’s inherent genetic predisposition to mount a response against alloantigens could 
be an additional important risk factor. HLA genes in this respect are particularly interesting 
because along with their polymorphisms, they have been related to autoimmune disorders 
and diseases which develop via T-cell mediated immunity45. Certain HLA (human leukocyte 
antigen) gene types indeed are similarly also associated with an enhanced response to red cell 
antigens like Fya (Duffy group), Jka (Kidd group) and K (Kell)46-48. Such evidence thus points 
to a set of genetic factors that predispose for being a responder17 (or a non-responder). 
Such “nature” related factors might be especially important for lending credibility to the 
“responder theory” discussed previously. In this respect the risk of alloimmunization varying 
according to clinical and environmental factors should be especially studied in patients with 
the most favorable genetic make up to mount humoral immunity against red blood cell 
antigens. The evidence for this however needs to be expanded.
What next?
An interesting way to study these genetic factors could be to look at genetic markers which 
influence immune system and vaccination efficiency. SNP’s in candidate genes (e.g. coding for 
HLA types) modulating specific and innate immune responses should be assessed. HLA types 
already implicated with some antigen groups should be extended to study for all the clinically 
relevant antigen types mentioned in the R-FACT study protocol. Admittedly, R-FACT study 
numbers so far are low to find any small effect. Merging the datasets and bio-banks (with 
stored patient tissue) with other ongoing initiative nationwide (or continent-wide) could yield 
potentially useful results. 
Transfusing patients based on these genetic types would be an elegant yet currently an 
expensive solution. Perhaps, identification of a high at- risk sub-population would make 
transfusions based on extensive phenotype matching more viable and cost effective. 
Given the evidence that we have been able to produce in our study population, with our 
study designs and the studied transfusion and patient risk factors; they could be tabulated 
as follows:
Transfusion and Patient risk factors Risk of alloimmunization
Number of transfusions Risk increases with the number of transfusions
Intensity of transfusions Similar risk in intensively and non- intensively transfused
Storage time of red cells Does not affect the risk of alloimmunization 
Patient Sex Does not affect the risk of alloimmunization
Patient Age Does not affect the risk of alloimmunization
Immune suppressant therapy Decreases the risk of alloimmunization
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Next, assessing the scientific evidence on clinical transfusion medicine research, we 
observed that the investigators tend to use principles from prediction research to answer 
etiologic research questions. This often results in misleading interpretation of risk factor 
findings at hand49-52. Therefore it seems warranted to question in studies on transfusion 
associated risk factors- if and how multivariate models are being used and interpreted; and 
if the important issue of confounding is properly dealt with. To first investigate the public 
acknowledgement of these issues, we used a questionnaire-based survey to quantify the 
proportion of 32nd meeting of the International Society of Blood Transfusion ISBT 2012, 
Cancun, Mexico visitors who felt confident with a causal interpretation of a stepwise logistic 
regression model. Thirty to 40% of the respondents agreed that a stepwise model was a 
valid method to adjust for confounding, and 60% of them agreed to a causal interpretation 
of a model built for prediction purposes. These findings suggest that a large proportion 
of ISBT visitors (transfusion medicine experts) often confuse etiology with prediction in the 
published transfusion medicine research. Conclusions in present literature based on flawed 
study designs, methods and analysis are thus not often questioned. Using these results as a 
platform, we aimed to delineate the distinction between etiologic and prediction research, 
issues of confounding accompanying these research aims and how a multivariate model deals 
with confounding. To this effect, our chapter 7 aims to provide an education based point of 
reference dealing with these issues.
Future research following our studies should pragmatically aim at identifying and studying 
other potential clinical risk or protective factors for alloimmunization. The research should 
be based on robust study designs and extensive data sets, inspired and aided by subject 
matter knowledge. Our ongoing R-FACT study (of which the first results are reported in 
this thesis) is in our mind an example of a setting wherein patient diagnosis, medication 
and therapy profiles, potentially immune modulating environmental factors in early life 
and importantly, certain HLA types, single nucleotide polymorphisms (SNPs) and other such 
indicators of humoral response can be studied extensively. The next step will be to combine 
the information from this thesis with the future results of the R-FACT study into, a clinical 
risk score to identify high (or low) risk groups for alloimmunization. Based on such a clinical 
prediction risk score – the eventual aim of the on-going R-FACT study – future patients might 
be selectively matched to their blood group phenotype. 
In conclusion, the results from this thesis point to an increase in the risk of alloimmunization 
with an increased number of transfusions. Intensity of red cell transfusions and the storage 
time of red blood cells do not influence the risk of alloimmunization. For recipient related 
factors, the results differ. Surprisingly, risk of alloimmunization does not differ between men 
and women. However, use of concomitant immunosuppressives in patients receiving red cell 
transfusions decreases the risk of alloimmunization. The conduct of observational studies like 
ours, that make use of existing datasets, presents greater demands than is often realized, and 
needs considerable amounts of thought about the study design and analysis. In the research 
literature about transfusion medicine the pitfalls of confounding by indication are often 
neglected, and associations are confused with causality. Therefore, caution is often needed to 
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interpret the results from the existing literature in our field. Apart from the findings reported 
in this thesis, we hope that the studies that are presented will engender a robust debate 
about how to conduct clinical observational research on the hazard of alloimmunization by 
transfusions. 
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A matched case- referent study was designed (presented in chapter 2) where a “clinical 
risk period for alloimmunization” was defined for cases as the period in which transfusion 
most likely caused the observed primary alloimmunization. Potential transfusion related 
risk factors and clinical risk factors were studied in this implicating period. We designed 
a new incident user cohort study in a general transfused patient population in chapter 3, 
and observed that the risk of alloimmunization increases up to 7% up until 40th transfused 
unit, and the risk was comparable between men and women. We then focused on the 
transfusion related risk factors for alloimmunization. Next, we studied if the storage time of 
transfused RBCs was a risk factor of alloimmunization in chapter 4; and found that given 
our study design and population, the storage time of RBCs is not associated with post-
transfusion risk of alloimmunization within the clinically relevant storage time ranges of 7-28 
days. In chapter 5, we examined the association between the transfusion intensity and the 
risk of clinically relevant RBC alloantibody formation in a previously non-transfused, non-
alloimmunized cohort using another incident new user cohort study design; and did not find 
a difference between the intensively transfused (with intensive transfusions studies separately 
as ≥5, ≥10 and ≥20 units transfused in 48 hours) and non-intensively transfused patients, 
and their risk of alloimmunization. In chapter 6, we showed that the use of corticosteroids 
and other immunosuppressants was associated with a lower risk of clinically relevant red cell 
alloantibodies against donor red blood cells. Finally, using results from ISBT 2012 conference 
at Cancun, we aimed to delineate the distinction between etiologic and prediction research, 
issues of confounding accompanying these research aims and how a multivariate model deals 
with confounding. To this effect we provided educational messages that might serve as a 





In hoofdstuk 2 hebben we een cohort gevolgd van patiënten die voor het eerst een 
transfusie ontvingen. Het risico op allo-immunisatie liep op tot 7% bij de 40st transfusie 
en was vergelijkbaar tussen mannen en vrouwen. Om transfusie-gerelateerde risicofactoren 
voor allo-immunisatie verder te onderzoeken hebben we vervolgens een gematchte case-
referent studie opgezet (zoals beschreven in hoofdstuk 3). Hierbij werd een “klinische 
risico periode voor allo-immunisatie” voor cases gedefinieerd als de periode waarin gegeven 
transfusies het de hoogste waarschijnlijkheid voor het veroorzaken van een primaire allo-
immunisatie hadden. Mogelijke transfusie-gerelateerd en klinische risicofactoren werden 
voor deze risico-periode geanalyseerd. Vervolgens onderzochten we in hoofdstuk 4 of de 
bewaarduur van RBC een risicofactor voor allo-immunisatie was. Met onze studie-opzet en 
binnen deze populatie vonden we geen associatie van klinische relevante bewaarduren van 
7-28 dagen met het risico op allo-immunisatie na transfusie. In hoofdstuk 5 onderzochten 
we of transfusie intensiteit geassocieerd was met het risico op klinisch relevante RBC allo-
antilichamen in niet eerder getransfundeerde en niet eerder ge-allo-immuniseerde patiënten 
en vonden geen verschil in het allo-immunisatie-risico tussen intensief getransfundeerde 
(gedefinieerd als ≥5, ≥10 en ≥20 eenheden binnen 48 uur) en niet-intensief getransfundeerde 
patiënten. In hoofdstuk 6 laten we zien dat het gebruik van corticosteroïden en andere 
immuunsuppressiva geassocieerd is met een lager risico op klinisch relevante allo-antilichamen 
tegen rode bloed cellen van de donor. Tot slot hebben we resultaten van een survey onder 
bezoekers van de ISBT 2012 in Cancun gebruikt om het onderscheid tussen etiologisch en 
predictie onderzoek duidelijk te maken en de verschillende rollen van confounding en het 
gebruik multivariate modellen in beide typen onderzoek te benadrukken. Hiertoe geven we 
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